

**Evidence-based Guideline: Evaluation, Diagnosis, and Management of  
Facioscapulohumeral Muscular Dystrophy**

Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine

Rabi Tawil, MD, FAAN<sup>1</sup>; John T. Kissel, MD, FAAN<sup>2</sup>; Chad Heatwole, MD, MS-CI<sup>3</sup>; Shree Pandya, PT, DPT, MS<sup>4</sup>; Gary Gronseth, MD, FAAN<sup>5</sup>; Michael Benatar, MBChB, DPhil, FAAN<sup>6</sup>

(1) MDA Neuromuscular Disease Clinic, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

(2) Department of Neurology, Wexner Medical Center, Ohio State University, Columbus, OH

(3) Department of Neurology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

(4) Department of Neurology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

(5) Department of Neurology, University of Kansas School of Medicine, Kansas City, KS

(6) Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL

Correspondence to:

American Academy of Neurology

[guidelines@aan.com](mailto:guidelines@aan.com)

Approved by the Guideline Development, Dissemination, and Implementation Subcommittee on July 23, 2014; by the AAN Practice Committee on October 20, 2014; by the AANEM Board of Directors on [date]; and by the AANI Board of Directors on [date].

**This guideline was endorsed by the FSH Society on December 18, 2014.**

## **AUTHOR CONTRIBUTIONS**

Rabi Tawil: study concept and design, acquisition of data, analysis or interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content, study supervision.

John Kissel: acquisition of data, analysis or interpretation of data, critical revision of the manuscript for important intellectual content.

Chad Heatwole: acquisition of data, analysis or interpretation of data, critical revision of the manuscript for important intellectual content.

Shree Pandya: acquisition of data, analysis or interpretation of data, critical revision of the manuscript for important intellectual content.

Gary Gronseth: study concept and design, acquisition of data, analysis or interpretation of data, study supervision.

Michael Benatar: study concept and design, acquisition of data, analysis or interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content, study supervision.

## **STUDY FUNDING**

Funding for this publication was made possible (in part) by grant DD10-1012 from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The remaining funding was provided by the American Academy of Neurology.

## **DISCLOSURE**

Dr. Tawil has served as a consultant for aTyr Pharma, Cytokinetics Inc., and Novartis; and received research funding support from the National Institutes of Health (NIH) and the FSH Society.

Dr. Kissel served on a scientific advisory board for and received travel funding from Cytokinetics.

Dr. Heatwole receives research funding support from the NIH and the New York State Empire Clinical Research Investigator Program.

Dr. Pandya reports no relevant disclosures.

Dr. Gronseth reports no relevant disclosures.

Dr. Benatar reports no relevant disclosures.

## **ABBREVIATIONS**

AAN: American Academy of Neurology

AANEM: American Association of the Neuromuscular & Electrodiagnostic Medicine

CI: confidence interval

*DUX4*: double homeobox 4

EVID: statements supported directly by the systematically reviewed evidence

FSHD: facioscapulohumeral muscular dystrophy

FSHD1: FSHD type 1

FSHD2: FSHD type 2

FVC: forced vital capacity

GDDI: Guideline Development, Dissemination, and Implementation Subcommittee

INFER: an inference from one or more of the other statements

kb: kilobase

MD: muscular dystrophy

MYO-029: myostatin inhibitor

PFT: pulmonary function testing

PIRP: Practice Issues Review Panel

poly-A: polyadenylation

PRIN: an accepted axiom or principle

QMT: quantitative isometric myometry test

QOL: quality of life

RELA: statements supported by strong evidence not included in the systematic review

SD: standard deviation



## **ABSTRACT**

**Objective:** To develop recommendations for the evaluation, diagnosis, prognostication, and treatment of facioscapulohumeral muscular dystrophy (FSHD) from a systematic review and analysis of the evidence.

**Methods:** Relevant articles were analyzed in accordance with the American Academy of Neurology classification of evidence schemes for diagnostic, prognostic, and treatment studies. Recommendations were linked to the strength of the evidence and other factors.

**Results and recommendations:** Available genetic testing for FSHD type 1 is highly sensitive and specific. Although respiratory insufficiency occurs rarely in FSHD, patients with severe FSHD should have routine pulmonary function testing. Routine cardiac screening is not necessary in patients with FSHD without cardiac symptoms. Symptomatic retinal vascular disease is very rare in FSHD. Exudative retinopathy, however, is potentially preventable, and patients with large deletions should be screened through dilated indirect ophthalmoscopy. The prevalence of clinically relevant hearing loss is not clear. In clinical practice, patients with childhood-onset FSHD may have significant hearing loss. Because undetected hearing loss may impair language development, screening through audiometry is recommended for such patients. Musculoskeletal pain is common in FSHD, and treating physicians should routinely inquire about pain. There is at present no effective pharmacologic intervention in FSHD. Available studies suggest that scapular fixation is safe and effective. However, these studies used different surgical approaches and rarely defined patient selection criteria. Surgical scapular fixation might be cautiously offered to selected patients. Aerobic exercise in FSHD appears to be safe and potentially beneficial. On the basis of the evidence, patients with FSHD might be encouraged to engage in low-intensity aerobic exercises.

## INTRODUCTION

Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of muscular dystrophy (MD), with a prevalence of approximately 1:15,000–1:20,000.<sup>e1,e2</sup> It is an autosomal dominant disorder; however, up to 30% of cases are sporadic, arising from de novo mutations. FSHD is characterized by a distinctive, initially regional distribution of muscle involvement. As the name implies, facial, periscapular, and humeral muscles typically are involved early in the disease course, although the deltoids are spared. This regional involvement, often asymmetric, leads to a distinctive appearance to the shoulders of straight clavicles and scapular winging on attempted shoulder abduction or forward flexion.<sup>e3</sup>

FSHD symptoms typically develop in the second decade of life but can begin at any age from infancy to late adulthood. As many as one-third of patients are asymptomatic, with the diagnosis made on the basis of previously unrecognized physical examination signs, present in more than 90% of patients by the age of 20.<sup>e1</sup>

Shoulder girdle weakness, often asymmetric, is the most common presenting symptom.

Weakness progresses in a descending manner to involve the upper arm muscles, then the trunk and abdomen, and then the lower extremities, especially the ankle dorsiflexors.

FSHD typically progresses slowly but variably.<sup>e4,e5</sup> About 20% of individuals with FSHD become wheelchair dependent after age 50.<sup>e1</sup> Clinically relevant extramuscular manifestations are uncommon in FSHD but can include respiratory compromise; retinal vascular disease that, in rare cases, leads to an exudative retinopathy and visual loss; hearing loss; and, possibly, an increased incidence of cardiac arrhythmias.

The molecular genetic basis of FSHD is complex. At the tip of chromosome 4q35 lies a repetitive 3.3 kb DNA sequence known as D4Z4 repeats.<sup>e6,e7</sup> Moreover, there are 2 different



DNA variants distal to the D4Z4 repeats, called the A and B allelic variants.<sup>e8</sup> FSHD type 1 (FSHD1), accounting for 95% of FSHD cases, results from deletion of a critical number of D4Z4 repeats, but only when this occurs on the A allele. The biological basis for this dual requirement is becoming increasingly understood. Contraction of the D4Z4 repeat results in a more open chromatin structure, allowing the potential expression of gene sequences within the repeats. One such gene, double homeobox 4 (*DUX4*), lacks the polyadenylation (poly-A) sequence required to produce stable messenger RNA.<sup>e9,e10</sup> Because only the A (not the B) allele variant contains a poly-A sequence, stable *DUX4* expression can occur only in the presence of the A allelic variant.<sup>e11,e12</sup>

Complicating matters is the existence of a genetically distinct but clinically identical FSHD type—FSHD type 2 (FSHD2)—now known to account for approximately 5% of patients with clinically defined FSHD.<sup>e13,e14</sup> Unlike the majority of patients with FSHD (i.e., FSHD1), patients with FSHD2 do not have contractions in the 4q35 D4Z4. As with FSHD1, and despite a normal number of repeats, the chromatin structure at the D4Z4 repeats is more open, and at least one 4q35 allele is an A variant.<sup>e13</sup> Recent studies have implicated mutations in *SMCHD1*, a gene on chromosome 18 that functions as a chromatin modifier, as the cause of the D4Z4 chromatin changes observed in about 85% of patients with FSHD2.<sup>e15</sup> Comprehensive molecular genetic testing for FSHD2 is complex and not readily available currently, and thus is not addressed in this guideline.

Despite having distinct genotypes, FSHD1 and FSHD2 have an identical molecular basis that results from the aberrant expression of the *DUX4* gene in skeletal muscle.<sup>e15,e16</sup> *DUX4* protein is a transcription factor normally expressed only in the germline, but little is known about its function.<sup>e17</sup> Preliminary evidence suggests that inappropriate expression of *DUX4* and its

transcriptional targets in skeletal muscle can result in apoptosis, impaired muscle regeneration, and induction of an immune response.<sup>e17</sup>

The clinical diagnosis of FSHD is based on the presence of a characteristic distribution of muscle weakness and is easily confirmed in most instances of FSHD1 by genetic testing. To date there is no effective treatment for muscle weakness in FSHD. Standard disease management includes physical therapy, bracing for foot drop, surgical scapular fixation in some patients, management of respiratory complications, and management and symptomatic treatment of extramuscular manifestations.

Previous FSHD practice guidelines have been based on consensus and expert opinion.<sup>e18,e19</sup> The present guideline, based on systematic review of the evidence, focuses exclusively on FSHD.

Duchenne MD and myotonic dystrophy will be discussed in forthcoming guidelines; limb-girdle muscular dystrophy and congenital MD are addressed in separate guidelines.<sup>e20,e21</sup> The present guideline addresses the following practical issues related to FSHD (reflective only of evidence relevant to FSHD1; no large FSHD2 clinical studies exist):

1. In regard to genetic testing, for patients with clinically defined FSHD (as determined by explicitly stated clinical criteria substantially similar to the consortium criteria),<sup>e22</sup> how often does D4Z4 contraction on 4q35 confirm the diagnosis of FSHD (irrespective of its occurrence on an allele A background)? For individuals who do not have FSHD, how often is a D4Z4 contraction on 4q35 found? For individuals who do not have FSHD, how often is a D4Z4 contraction on 4q35 on allele A found?
2. Among patients with FSHD, which factors are associated with or predict loss of clinically meaningful milestones (e.g., loss of independent ambulation)?

3. Among patients with FSHD, how frequent are respiratory abnormalities, cardiac abnormalities, retinal disease, hearing loss, and pain?
4. In regard to treatment, do interventions (as compared with no intervention) improve patient-relevant outcomes? Are there features that identify patients who are more or less likely to improve with a specific intervention?

### **DESCRIPTION OF THE ANALYTIC PROCESS**

In July 2010, the Guideline Development, Dissemination, and Implementation Subcommittee (GDDI) of the American Academy of Neurology (AAN) and the Practice Issues Review Panel (PIRP) of the American Association of the Neuromuscular & Electrodiagnostic Medicine (AANEM) convened a panel of clinicians with expertise in FSHD (see appendices e-1 and e-2 for a listing of the members of the AAN GDDI and AANEM PIRP). In accordance with the processes outlined in the 2004 and 2011 AAN guideline development manuals,<sup>e23,e24</sup> the panel searched the Medline, EMBASE, Cochrane, and Scopus databases from 1948 to October 2012 for relevant peer-reviewed articles in humans and in all languages (see appendix e-3 for search strategies). The initial search yielded 977 abstracts. Of those, 176 were obtained for full-text review. Each of the 176 articles was reviewed by 2 panel members working independently of each other. A total of 94 articles were selected for inclusion in the analysis, and of those, 76 articles were selected for evidence rating. An updated literature search completed in January 2014 identified an additional 12 potentially relevant articles, 4 of which were selected for evidence rating.

Selected articles contained information relevant to the 4 questions posed above and had acceptable study designs, including randomized, controlled trials; cohort studies; case-control

studies; and case series. Reviews and meta-analyses were excluded, as were studies with 6 or fewer participants for studies of FSHD complications and prognosis, fewer than 9 participants for genetic screening, and fewer than 5 participants for treatment. Also excluded were studies not relevant to the clinical questions, studies including participants who had unrelated diseases or were outside of the study population, and articles that were not peer reviewed. Each of the 76 articles was rated by 2 panel members using the AAN criteria for classification of screening, prognostic, and treatment articles (appendix e-4).

The panel formulated a rationale for recommendations based on the evidence systematically reviewed and stipulated axiomatic principles of care. This rationale is explained in a section that precedes each set of recommendations. From this rationale, corresponding actionable recommendations were inferred. The level of obligation of the recommendations was assigned using a modified Delphi process that considered the following prespecified domains: the confidence in the evidence systematically reviewed, the acceptability of axiomatic principles of care, the strength of indirect evidence, and the relative magnitude of benefit to harm. Additional factors explicitly considered by the panel that could modify the level of obligation include judgments regarding the importance of outcomes, cost of compliance with the recommendation relative to benefit, the availability of the intervention, and anticipated variations in patients' preferences. The prespecified rules for determining the final level of obligation from these domains are indicated in appendix e-5. The level of obligation was indicated using standard modal operators. *Must* corresponds to *Level A*, very strong recommendations; *should* to *Level B*, strong recommendations; and *might* to *Level C*, weak recommendations. The panel members' judgments supporting the levels of obligation are indicated in appendix e-6.

## ANALYSIS OF EVIDENCE

### FSHD genetic testing.

#### *Clinical questions.*

Understanding the molecular genetics of FSHD1 is critical to the molecular diagnosis of this disorder. Healthy individuals possess at least 11 D4Z4 repeats, yielding a DNA fragment >38 kb on standard genetic testing. Affected individuals, in contrast, possess between 1 and 10 repeats, yielding DNA fragments 10 to 38 kb in size.<sup>e7</sup> Measurement of the size of the residual D4Z4 sequence on 4q35 forms the basis for genetic testing in FSHD. As previously discussed, an additional requirement for FSHD identification is that the contraction occur on the A allelic variant. Routine first-pass commercial genetic testing in the United States measures the residual D4Z4 repeat sizes without determining the A or B allelic variants. The prevalence of D4Z4 repeat sizes in the range of 1 to 10 alleles is low in the general population. This low prevalence raises questions about the clinical utility of routine determination of the A/B variant in molecular confirmation of FSHD. The following specific clinical questions were examined:

- For patients with clinically defined FSHD (as determined by explicitly stated clinical criteria substantially similar to the consortium criteria), how often does D4Z4 contraction on 4q35 confirm the diagnosis of FSHD (irrespective of its occurrence on an allele A background)?
- For individuals who do not have FSHD, how often is a D4Z4 contraction on 4q35 found?
- For individuals who do not have FSHD, how often is a D4Z4 contraction on 4q35 on allele A found?

#### *Analysis.*

Nine Class III studies containing information relevant to the questions above were reviewed.<sup>e25–e33</sup> The studies were rated Class III primarily because the patient populations studied were recruited from specialty clinics, which increases the risk of referral bias.

All 9 Class III studies addressed the question of the sensitivity of the D4Z4 contraction on 4q35 for the diagnosis of FSHD.<sup>e25–e33</sup> In these studies FSHD was defined by standard clinical criteria. In most of the studies the deletion was detected by measurement of allele size through use of the standard p13E-11 probe proximal to the D4Z4 repeat and genomic DNA digested with EcoRI and BlnI restriction enzymes. The frequency of D4Z4 contractions among patients with clinically defined FSHD ranged from 86% to 100%. There was statistical heterogeneity in the results ( $I^2 = 0.65$ ). Some of the heterogeneity in the studies could be accounted for by the varying definitions for the upper limit in the size of a deleted allele (range: 28–38 kb). The pooled estimate of the sensitivity of the presence of D4Z4 contraction (random effects) was 93% (95% confidence interval [CI] 88%–96%). The confidence in the evidence was graded as moderate (upgraded from low because of the magnitude of the effect).

These 9 studies also contained evidence in regard to the specificity of the presence of the D4Z4 contraction.<sup>e25–e33</sup> One of the studies was excluded because the genetic testing was done using a single digestion with EcoRI, which could result in false-positive contraction on the homologous region on chromosome 10.<sup>e28</sup> The frequency of D4Z4 contractions in normal controls ranged from 0% to 9%. The pooled estimate of the specificity of the presence of D4Z4 contraction (random effects) was 99% (95% CI 97%–100%). The confidence in the evidence was graded as moderate (upgraded from low because of the magnitude of the effect).

A single Class III study contained evidence in regard to the specificity of the presence of a D4Z4 contraction on an A allele background.<sup>e29</sup> This study found that 11 out of 801 normal individuals

carried a contracted allele on an A allele background (specificity 98%; 95% CI 97.5%–99.2%).

The confidence in the evidence was graded as low (upgraded from very low because of the magnitude of the effect).

### ***Conclusions.***

The finding of a D4Z4 contraction on chromosome 4q35 likely has a sensitivity of 93% and a specificity of 98% for the diagnosis of clinically defined FSHD (9 Class III studies).<sup>e25–e33</sup> In a patient population with clinically defined FSHD, the degree of specificity is not likely to be further enhanced by testing for presence of the A variant.

### **Risk factors for disease severity.**

#### ***Clinical question.***

A critical aspect of management of patients with any neuromuscular disorder lies in identifying clinical, biochemical, or genetic aspects of the illness associated with prognosis. It is indispensable to identify such risk factors that might be linked to a severe (or more benign) course when discussing prognosis with patients, designing therapy programs and other meaningful interventions, and helping patients make important medical, financial, and other life decisions. This is true particularly in a disease such as FSHD where there is tremendous variability in the extent and severity of involvement. For this analysis, relevant studies were reviewed to address the following specific question: Among patients with FSHD, which factors are associated with or predict loss of clinically meaningful milestones (e.g., loss of independent ambulation)?

#### ***Analysis.***

Seven studies containing information relevant to this question were reviewed.<sup>e30,e34–e39</sup> One study was performed before accurate genetic testing was available and was not considered further.<sup>e36</sup> The remaining studies explored the prognostic effects of 2 risk factors: age at symptom onset and D4Z4 repeat size. Five studies examined the relationship between D4Z4 repeat size and severity.<sup>e30,e34,e35,e38,e39</sup> A Class I study in a cohort of 313 patients showed a linear relationship between age at diagnosis and repeat size. The study also showed that the age at which patients started using wheelchairs is associated with D4Z4 repeat size: 24.1 years (CI 17.0–31.3) for repeat sizes of <18 kb, 48 years (CI 44.0–52.3) for repeat sizes of 19 to 28 kb, and 58.6 years (CI 52.2–64.9) for repeat sizes of > 28 kb.<sup>e38</sup> A Class II study found a similar correlation between age at loss of ambulation and repeat size ( $r = 0.773$ ,  $p < 0.001$ ).<sup>e39</sup> Another Class II study in a cohort of 165 patients with FSHD found an inverse correlation between fragment size and clinical severity as assessed by degree of leg weakness and a global clinical severity score.<sup>e30</sup> Severe lower-limb involvement was found in 100% of patients with an EcoRI fragment size of 10 to 13 kb, in 53% of patients with a fragment size of 16 to 20 kb, and in only 19% of patients with a fragment size larger than 21 kb. In this study 36% of the variation in the severity of lower-limb involvement was explained by fragment size. There was no significant correlation found between fragment size and age at loss of ambulation. In a Class III study of 7 de novo patients, quantitative isometric myometry test (QMT) scores normalized for age, sex, and height were used to quantify overall disease severity. This analysis found a significant ( $r = 0.92$ ,  $p < 0.004$ ) correlation between disease severity and the size of the 4q35-associated deletion.<sup>e36</sup> A Class II study of 65 patients, however, found no correlation between Clinical Severity Scale scores and fragment size or between fragment size and physical function on the SF-36 quality of life (QOL)



scale; however, on the physical function subscore of this scale, patients with fragment sizes <18 kb had lower scores ( $p$  value not reported).<sup>e37</sup>

A single Class III study addressed the question of whether age at onset affected disease severity.<sup>e34</sup> This study found a significant correlation between proband age at onset and FSHD-associated fragment size ( $r = 0.56, p < 0.001$ ). A similar correlation ( $r = 0.70, p < 0.01$ ) with fragment size was observed for age at loss of ambulation in 16 patients using a wheelchair.

### ***Conclusions.***

In patients with FSHD, smaller D4Z4 repeat size is probably associated with more severe disease as measured by age at diagnosis and age at wheelchair dependence (1 Class I study).<sup>e38</sup> Other measures of disease severity possibly associated with smaller fragment size include quantitative computerized muscle testing, severity of leg weakness, global severity scores, and earlier loss of ambulation (one Class II study or multiple Class III studies).<sup>e30,e34,e35,e39</sup> Earlier age at onset is also possibly associated with smaller fragment size and earlier loss of ambulation (one Class III study).<sup>e34</sup> Patients with very large deletions (EcoRI fragment sizes of 10–15 kb) are particularly prone to severe disease.

### ***Complications.***

#### ***Clinical question.***

Although the cardinal features of FSHD involve limb weakness that starts with focal weakness of the shoulders, face, and humeral muscles, additional systemic features may occur. These extramuscular features may have significant and, at times, life-threatening consequences. It is important for clinicians to recognize the association between these manifestations and the presence of FSHD so that needed monitoring, counseling, and early interventions may be

implemented. The following specific clinical question was examined: Among patients with FSHD, how frequent are respiratory abnormalities, cardiac abnormalities, retinal disease, hearing loss, and pain?

***Analysis.***

*Respiratory abnormalities.* One Class II study, 1 Class III study, and 1 Class IV study were analyzed.<sup>e36,e40,e41</sup> In the Class II study, 10 patients with FSHD with respiratory insufficiency requiring nocturnal ventilator support were identified in a Dutch FSHD population of 800 patients, representing an estimated prevalence of 1.25% (95% CI 0.5%–2%).<sup>e40</sup> The Class III study examined pulmonary function testing (PFT) in 23 of 53 patients with FSHD.<sup>e36</sup> All patients had clinically defined FSHD, but it was not genetically confirmed. Of the 23 patients tested, 3 or 13% (95% CI 0.7%–27%) had a severe restrictive pattern on PFT. In contrast, the Class IV study selected 16 patients with genetically confirmed FSHD who were ambulant but severely affected and found only mild signs of a restrictive pattern on PFT in some patients (forced vital capacity [FVC] range 85%–117% predicted).<sup>e41</sup>

*Cardiac abnormalities.* Four Class III studies using electrocardiography/echocardiography found no structural abnormalities in 80 patients with FSHD (95% CI 0%–4.6%).<sup>e42–e45</sup> Six Class III studies examined surface electrocardiogram/echocardiogram in a combined total of 227 patients with FSHD.<sup>e36,e42–e46</sup> Abnormalities were found in 89 or 39.2% (95% CI 33.1%–45.7%) of patients screened. The same 6 Class III studies looked at the frequency of symptomatic or inducible supraventricular arrhythmias and found these in 22 patients or 9.7% (95% CI 6.5%–14.2%).

*Retinal vascular disease.* Four Class III studies examined the frequency of retinal vascular abnormalities on dilated eye examination or fluorescein angiography in 294 patients.<sup>e47–e50</sup> Of

those screened, 15 or 25% (95% CI 20.9%–30.8%) had retinal vascular abnormalities. One of the Class III studies, examining 396 patients with genetically confirmed FSHD, identified 3 patients with symptomatic retinal vascular disease.<sup>e50</sup> For the 4 studies, the combined proportion of patients with FSHD who had symptomatic retinal disease is 0.6% (95% CI 0.2%–1.5%).<sup>e47–e50</sup> In the previously mentioned study, a patient survey and literature review of patients with FSHD who had Coats disease, a total of 14 patients were identified; all but one had very large deletions (< 20 kb).<sup>e50</sup>

*Hearing loss.* Eight Class III studies used audiometry to examine hearing in a combined total of 394 patients. Of the patients examined, 61 or 15.5% (95% CI 12.1%–19.4%) had audiometric abnormalities.<sup>e26,e33,e47–e49,e51–e53</sup> In one of the studies, 3 of 4 patients followed with sequential audiometry over a 5-year period showed worsening hearing loss by audiogram.<sup>e53</sup> In addition, as in symptomatic retinal vascular disease, hearing loss occurs only in patients with large deletions ( $\leq$ 20 kb); hearing loss occurs in 32% (95% CI 16.7%–51.4%) of patients with large deletions.<sup>e53</sup> This observation is supported by a study of patients with FSHD and both symptomatic retinal vasculopathy and large deletion size.<sup>e50</sup> Of the 14 patients identified, 57% (95% CI 29.0%–82.3%) had hearing loss, 35.7% of whom required hearing aids.<sup>e50</sup>

*Pain.* One Class II study and 2 Class III studies examined the frequency of pain in a combined total of 376 patients with FSHD.<sup>e37,e54,e55</sup> Of those surveyed, 297 or 79% (95% CI 74.6%–82.8%) complained of pain. A single study assessed the severity of pain. Of 65 patients in that study, 8 or 10.8% (95% CI 3.2%–18.3%) had clinically significant pain.<sup>e37</sup> The most common sites of pain are, in descending order, the lower back, the legs, the shoulders, and the neck.<sup>e54</sup>

***Conclusions.***

*Respiratory abnormalities.* Evidence suggests that respiratory insufficiency and reduced pulmonary function may occur. However, there is insufficient evidence to determine the frequency and severity of respiratory compromise in patients with FSHD (1 Class II study<sup>e40</sup> and 1 Class III study<sup>e36</sup>).

*Cardiac abnormalities.* The prevalence of structural cardiac abnormalities on electrocardiography/echocardiography is possibly zero, but precision of this estimate cannot exclude a frequency of up to 4.6%. Although symptomatic or inducible supraventricular arrhythmias are found in patients with FSHD, because of the risk of referral bias there is insufficient evidence to determine the frequency of clinically relevant supraventricular arrhythmias (multiple Class III studies).<sup>e36,e42–e46</sup>

*Retinal vascular disease.* Confidence in the evidence for the prevalence of retinal vascular abnormalities is low, with up to 25% (95% CI 20.9%–30.8%) showing abnormalities on examination. However, only 0.6% (95% CI 0.2%–1.5%) of patients with FSHD develop symptomatic retinal disease (4 Class III studies).<sup>e47–e50</sup>

*Hearing loss.* Confidence in the evidence for the prevalence of audiometric abnormalities is very low due to the wide range of prevalence reported, ranging from rates equivalent to a normal matched control population to a prevalence of 64%. One study that correlated hearing loss with genotype suggests that only patients with large deletions, who represent about 15% of all patients with FSHD, are susceptible to hearing loss.<sup>e53</sup> Poor representation of this subgroup in some studies could account for the wide range of prevalence.

*Pain.* There is a high prevalence of pain in patients with FSHD, likely up to 79%, with a low level of confidence in the evidence (1 Class II study and 2 Class III studies).<sup>e37,e54,e55</sup> However,

the prevalence of clinically significant pain, as reported in a single Class III study, is likely much lower at 10.8%.<sup>e37</sup>

## **Treatment.**

### ***Clinical questions.***

The goal of therapy in FSHD is to improve muscle strength or function, or both. Until recently the underlying pathophysiology of FSHD was unknown, and thus pharmacologic trials have focused on improving muscle mass and strength, whereas surgical studies of scapular fixation have been motivated by efforts to improve function notwithstanding the presence of weakness. The trial of albuterol, for example, was based on animal studies showing an anabolic effect of the similar  $\beta$ 2-agonist drug clenbuterol. Likewise, the discovery of myostatin as an inhibitor of muscle growth has generated an interest in the use of myostatin inhibitors (such as MYO-029) in the hope that these would lead to increased muscle mass and strength. In the absence of effective pharmacologic therapy, a number of strategies have been used to address the problem of weakness of scapular stabilizers, as scapular destabilization is the most prominent manifestation of the disease, affecting more than 90% of individuals.<sup>e38</sup> This has proven stubbornly refractory to effective bracing, providing a motivation for surgical fixation in carefully selected patients. Relevant studies that were reviewed include studies on pharmacologic interventions, exercise, and surgical scapular fixation, or a combination of these modalities. The following questions were examined:

- Do interventions (as compared with no intervention) improve patient-relevant outcomes?
- Are there features that identify patients who are more or less likely to improve with a specific intervention?

## ***Analysis.***

*Pharmacologic interventions.* Three Class I studies of pharmacologic interventions provided pertinent information. Two randomized, controlled trials (Class I) examined the effect of oral albuterol on strength in FSHD, in one study after 12 months of treatment and in the second study after 6 months of treatment.<sup>e56,e57</sup> One study showed no effect on a global measure of strength based on QMT.<sup>e57</sup> The other study showed a clinically unimportant increase in the strength of 7 of 12 muscles measured by QMT.<sup>e56</sup> A third Class I randomized, controlled study examined the effect of an IV myostatin inhibitor (MYO-029) and showed no significant improvement in muscle strength.<sup>e58</sup> Three additional studies of pharmacologic intervention in FSHD were excluded because all were graded Class IV. One study examined the effect of prednisone on strength, a second study examined the effect of diltiazem on strength, and a third study examined the effect of albuterol on pain and fatigue.<sup>e59,e60,e61</sup> All three studies showed no beneficial effect.

*Surgical scapular fixation.* Eleven studies were reviewed on scapular fixation surgery; one was Class III and 10 were Class IV.<sup>e62—e72</sup> All the studies were uncontrolled case series and involved different surgical approaches. The consistency of the response on parameters of shoulder function (forward flexion, abduction, and pain) resulted in the upgrading of the confidence in the studies from very low to low.

*Exercise.* Two studies provided relevant information on the role of exercise. One 52-week Class I study examined the effect of strength training on muscle strength and showed no evidence of improved isometric strength testing; however, it showed improvement of significant but questionable importance in dynamic strength in 1 of 2 muscle groups tested.<sup>e59</sup> A single Class III study of 8 patients with FSHD showed that 12 weeks of low-intensity aerobic exercise improved

VO<sub>2</sub> max by 16% (standard deviation [SD] 3;  $p < 0.002$ ) and workload by 17% (SD 4;  $p < 0.002$ ), as well as self-reported levels of activity, without evidence of muscle damage.<sup>e73</sup>

### **Conclusions.**

*Pharmacologic interventions.* It is highly likely that albuterol is ineffective for improving muscle strength (2 Class I studies).<sup>e56,e57</sup> However, there is insufficient evidence to judge the efficacy of albuterol for muscle pain and fatigue (single Class IV study).<sup>e59</sup> The myostatin inhibitor MYO-029 is probably ineffective for improving muscle strength, pulmonary function, timed function, and QOL (single Class I study).<sup>e58</sup> There is insufficient evidence to support or refute the effects of prednisone (single Class IV study) or diltiazem (1 Class IV study) on muscle strength.<sup>e60,e61</sup>

*Surgical scapular fixation.* Scapular fixation is possibly effective for improving shoulder abduction and anterior flexion (1 Class III study, 9 Class IV studies) as well as shoulder pain (2 Class IV studies).<sup>e62–e72</sup> (The confidence in the evidence for scapular fixation was upgraded from very low to low because of the magnitude of effect.)

*Exercise.* On the basis of a single Class I study, strength-training exercise is probably ineffective for improving muscle strength meaningfully (1 Class I study).<sup>e59</sup> There is evidence that supports the use of aerobic exercise in FSHD, but the confidence in the evidence, based on a single Class III study, is very low.<sup>e73</sup>

## **PRACTICE RECOMMENDATIONS**

The recommendations below encompass four major areas: diagnosis, predictors of severity, surveillance for complications, and treatment of FSHD. Each recommendation is preceded by a clinical context section that outlines the evidence, general principles of care, and evidence from related disorders that inform the recommendations.

Because of the relative paucity of literature directly relevant to FSHD, for some of the clinical questions, some of the recommendations below are based in part on evidence from other neuromuscular disorders.

### **Diagnosis of FSHD.**

See also the algorithm in figure e-1.

#### ***Clinical context.***

When clinical presentation of FSHD is typical and the inheritance pattern is consistent with autosomal dominant inheritance, clinical diagnosis is usually straightforward. If, in such circumstances, the diagnosis is genetically confirmed in a first-degree relative, genetic testing is not necessary for each affected individual. However, atypical presentations are not uncommon. In the setting of atypical or sporadic cases, genetic confirmation is important for genetic counseling, especially with the recent discovery of 2 genetically distinct forms of FSHD (PRIN). In the most common FSHD type, FSHD1, disease results from contraction of a DNA repeat sequence, termed *D4Z4 repeat*, on one copy of 4q35 from more than 10 repeats to 1 to 10 repeats. In addition, the contraction must occur in the presence of one particular (A variant) of 2 (A/B) sequence variants distal to the repeats (PRIN). Available molecular testing for FSHD1, which measures only the presence of a repeat contraction on initial testing, is highly sensitive and specific (EVID). In studies that utilized strict diagnostic criteria for FSHD, determining whether a contraction occurs on an A variant genetic background does not appear to improve diagnostic specificity (EVID). However, in clinical practice, strict clinical diagnostic criteria might not be adhered to, increasing the chances of a false-positive result (INFER). In



consequence, determining that a D4Z4 contraction is occurring on an A variant is warranted when the clinical presentation is atypical for FSHD. At present, commercial genetic testing in FSHD is limited to FSHD1 testing.

***Recommendation.***

A1. Clinicians should obtain genetic confirmation of FSHD1 in patients with atypical presentations and no first-degree relatives with genetic confirmation of the disease (Level B).

Figure e-1 shows the recommended FSHD molecular diagnosis decision tree.

**Predictors of severity in FSHD.**

***Clinical context.***

Factors that predict disease severity in FSHD are important for counseling patients and for screening for and managing potential complications (PRIN). The D4Z4 deletion size appears to be somewhat predictive of the overall rate of disease progression (EVID). D4Z4 deletion size should be used cautiously for predicting disease progression rate in any particular individual due to other sources of variation affecting disease severity, including intrafamilial factors (INFER). Clinical experience suggests that patients with severe childhood-onset disease almost invariably have very large deletions (i.e., contracted D4Z4 allele of 10–20 kb or 1–4 repeats), suggesting a much more robust correlation between disease severity and large deletions (EVID).

***Recommendation.***

B1. Large D4Z4 deletion sizes (contracted D4Z4 allele of 10–20 kb) should alert the clinician that the patient is more likely to develop more significant disability and at an earlier age. Patients with large deletions are also more likely to develop symptomatic extramuscular manifestations (Level B). (See next section on monitoring for FSHD complications.).

## **Monitoring for complications of FSHD.**

### ***Pulmonary complications.***

*Clinical context.* Our systematic review revealed that some patients with FSHD develop respiratory muscle weakness that can result in respiratory failure and need for mechanical ventilator assistance (e.g., nocturnal bilevel positive airway pressure), although this complication is uncommon (EVID). Patients with chronic respiratory failure from neuromuscular-related weakness often do not have classic symptoms of ventilatory failure (i.e., overt dyspnea). Impending respiratory failure, therefore, may begin with respiratory insufficiency mainly during sleep, resulting in excessive daytime somnolence or nonrestorative sleep. Respiratory insufficiency in patients with FSHD, therefore, may be evident only through pulmonary function testing (PRIN). Respiratory failure constitutes a major source of morbidity in patients with most MD types and can severely disrupt sleeping, daily activities, and QOL (PRIN). Early intervention with noninvasive mechanical ventilation leads to improved survival and QOL (RELA).<sup>e74</sup>

### ***Recommendations.***

C1. Clinicians should obtain baseline pulmonary function tests on all patients with FSHD. Patients should be monitored regularly if they have abnormal baseline pulmonary function test results or any combination of severe proximal weakness, kyphoscoliosis, wheelchair dependence, or comorbid conditions that may affect ventilation (e.g., chronic obstructive pulmonary disease, cardiac disease) (Level B).

C2. In patients who have FSHD and either 1) compromised pulmonary function studies (e.g., FVC <60%) or 2) symptoms of excessive daytime somnolence or nonrestorative sleep (e.g., frequent nocturnal arousals, morning headaches), clinicians should refer patients for pulmonary or sleep medicine consultation for consideration of nocturnal sleep monitoring or nocturnal noninvasive ventilation in order to improve QOL (Level B).

C3. Patients with FSHD who do not get regular pulmonary function testing should be tested prior to surgical procedures requiring general anesthesia, as such testing may uncover asymptomatic respiratory compromise (Level B).

#### ***Cardiac abnormalities.***

*Clinical context.* Our systematic review revealed very little evidence for structural cardiac abnormalities in FSHD. Also, data are insufficient to suggest that patients with FSHD are susceptible to cardiac arrhythmias (EVID). Routine electrocardiographic or echocardiographic testing is therefore unnecessary in patients with FSHD who are asymptomatic (INFER).

#### *Recommendation.*

C4. Patients with FSHD should be referred for cardiac evaluation if they develop overt signs or symptoms of cardiac disease (e.g., shortness of breath, chest pain, palpitations). However, routine cardiac screening is not essential in the absence of cardiac signs or symptoms (Level C).

#### ***Retinal vascular disease.***

*Clinical context.* Our systematic review suggests that symptomatic retinal vascular disease in the form of an exudative retinopathy (Coats disease) is very rare in FSHD but tends to affect patients

with large deletions almost exclusively (EVID). Untreated exudative retinopathy can lead to significant visual loss, which may be prevented by early intervention (INFER).

*Recommendation.*

C5. Clinicians should refer patients with FSHD and large deletions (contracted D4Z4 allele of 10–20 kb) to an experienced ophthalmologist (e.g., retina specialist) for dilated indirect ophthalmoscopy (Level B). The presence and severity of retinal vascular disease at initial screening should be used to determine the frequency of subsequent monitoring (Level B).

***Hearing loss.***

*Clinical context.* Our systematic review shows that the available studies fail to capture the prevalence and clinical relevance of hearing loss in FSHD (EVID). In clinical practice, most patients with FSHD and hearing loss requiring the use of a hearing aid have childhood-onset FSHD with large D4Z4 deletions. Two recent studies support this clinical impression (EVID). Moreover, one of the studies suggests that hearing loss is progressive in some patients. Adults and older children are cognizant of the hearing loss onset, and therefore intervention can occur early when required. However, failure to detect hearing loss in infants and younger children may significantly delay or impair language development (PRIN).

*Recommendation.*

C6. Clinicians should screen all young children with FSHD at diagnosis and yearly thereafter until these children start school, as hearing loss may not be present at diagnosis and can be progressive (Level B).

***Pain.***

*Clinical context.* Pain is a common complaint in FSHD and appears to be mostly musculoskeletal in origin (EVID). Pain compounding muscle weakness can have a significant impact on QOL (INFER). Physical therapists often can provide insight into the mechanism of pain in patients with weakness (PRIN). Nonsteroidal anti-inflammatory medications are useful for acute pain, and antidepressants or antiepileptics, for chronic musculoskeletal pain (PRIN).

*Recommendation.*

C7. Treating physicians should routinely inquire about pain in patients with FSHD. Referral for a physical therapy evaluation may prove helpful as an initial nonpharmacologic intervention. In patients with persistent pain and no contraindications, a trial of nonsteroidal anti-inflammatory medications is appropriate for acute pain and antidepressants or antiepileptics for chronic pain (Level B).

## **Treatment of FSHD.**

### ***Pharmacologic interventions.***

*Clinical context.* As of this writing, no evidence exists for any effective pharmacologic interventions that improve strength or slow disease progression in FSHD. Randomized, controlled trials of albuterol were negative (EVID). Uncontrolled, open-label trials of corticosteroid and diltiazem showed no benefit. A controlled early phase II study of MYO-029, a myostatin inhibitor, also failed to show benefit.

*Recommendation.*

D1. In patients with FSHD, clinicians should not prescribe albuterol, corticosteroid, or diltiazem for improving strength (Level B).

### ***Surgical scapular fixation.***

*Clinical context.* In patients with FSHD, limited shoulder range of motion due to periscapular muscle weakness is a major source of functional limitation (PRIN). Moreover, in many patients, bedside manual scapular fixation can result in significant improvement in shoulder range of motion (PRIN). Postoperative complications are infrequent but include hemo- or pneumothorax, pain, infection, non-union, and reduced lung capacity. Scapular fixation appears to be generally safe and may be effective for improving shoulder range of motion (EVID).

### ***Recommendation.***

D2. Surgical scapular fixation might be offered cautiously to selected patients after careful consideration of the overall muscle impairment in the involved arm, assessment of potential gain in range of motion by manual fixation of the scapula, the patient's rate of disease progression, and the potential adverse consequences of surgery and prolonged postsurgical bracing (Level C).

### ***Aerobic exercise.***

*Clinical context.* Aerobic exercise in FSHD appears to be safe and potentially beneficial (EVID), as has been shown in many other muscle diseases (RELA).<sup>e75</sup> Aerobic fitness is important for overall health (PRIN). To minimize injury from falls or overuse, the type of aerobic exercise should be tailored to the patient's particular distribution of weakness. For example, a stationary bicycle rather than a treadmill should be recommended for patients with leg weakness (PRIN). Although no data exist to suggest that strength training is detrimental in FSHD (EVID), further research is needed to determine whether such strength training will result in clinically meaningful long-term functional improvement (INFER).

### ***Recommendations.***

D3. Clinicians might encourage patients with FSHD to engage in low-intensity aerobic exercise. An experienced physical therapist can help guide development of individualized exercise programs. Clinicians might also use the practical physical activities guidelines for individuals with disabilities, provided by the US Department of Health and Human Services, when counseling patients about aerobic exercise (Level C).<sup>e76</sup>

D4. In patients interested in strength training, clinicians may refer patients to physical therapists to establish a safe exercise program using appropriate low/medium weights/resistance that takes into consideration the patients' physical limitations (Level C).

## **RECOMMENDATIONS FOR FUTURE RESEARCH**

- Future studies in FSHD should employ a clinical definition of disease based on consensus criteria combined with molecular genetic diagnosis.
- Observational studies (e.g., case-control and cohort) should conform to the Strengthening the Reporting of Observational Studies in Epidemiology criteria for reporting of results, leading to higher confidence in the published evidence.<sup>e77</sup>
- Patients with childhood-onset FSHD appear to have more severe neuromuscular manifestations as well as more clinically significant extramuscular complications.

Understanding what risk factors predispose this subpopulation of patients with FSHD to such extramuscular manifestations is important for developing specific management strategies. A concerted effort is needed to study such patients with clearly defined clinical and genetic parameters.

- Use of patient registries will allow researchers to access more patients and obtain more robust data on risk factors and prognostic factors. Such a registry exists in the United States, and others are being developed elsewhere.



## **DISCLAIMER**


Clinical practice guidelines, practice advisories, systematic reviews and other guidance published by the American Academy of Neurology and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information: 1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; 2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); 3) addresses only the question(s) specifically identified; 4) does not mandate any particular course of medical care; and 5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. AAN provides this information on an “as is” basis, and makes no warranty, expressed or implied, regarding the information. AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

## **CONFLICT OF INTEREST**

The American Academy of Neurology and American Association of Neuromuscular & Electrodiagnostic Medicine are committed to producing independent, critical, and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the

AAN and AANEM keep separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. AAN and AANEM limit the participation of authors with substantial conflicts of interest. The AAN and AANEM forbid commercial participation in, or funding of, guideline projects. Drafts of the guideline have been reviewed by at least three AAN committees, at least one AANEM committee, a network of neurologists, *Neurology* peer reviewers, and representatives from related fields. The AAN Guideline Author Conflict of Interest Policy can be viewed at [www.aan.com](http://www.aan.com). For complete information on this process, access the 2004 AAN process manual.<sup>e23</sup>

**Figure e-1. Recommended diagnostic flowchart for FSHD**



def. = deficiency; FSHD = facioscapulohumeral muscular dystrophy; FSHD1 = FSHD type 1; FSHD2 = FSHD type 2; LGMD2A = limb-girdle muscular dystrophy type 2A.

### **Appendix e-1. AAN GDDI members and mission**

The mission of the GDDI is to develop, disseminate, and implement evidence-based systematic reviews and clinical practice guidelines related to the causation, diagnosis, treatment, and prognosis of neurologic disorders.

The GDDI is committed to using the most rigorous methods available within its budget, in collaboration with other available AAN resources, to most efficiently accomplish this mission.

Cynthia Harden, MD (Chair); Steven R. Messé, MD (Co-Vice-Chair); Sonja Potrebic, MD, PhD (Co-Vice-Chair); Eric J. Ashman, MD, FAAN; Richard L. Barbano, MD, PhD, FAAN; Brian Callaghan, MD; Jane Chan, MD, FAAN; Diane Donley, MD; Richard M. Dubinsky, MD, MPH, FAAN; Terry Fife, MD, FAAN; Jeffrey Fletcher, MD; Michael Haboubi, MD; John J. Halperin, MD, FAAN; Yolanda Holler, MD; Andres M. Kanner, MD; Annette M. Langer-Gould, MD, PhD; Jason Lazarou, MD; Nicole Licking, DO; David Michelson, MD; Pushpa Narayanaswami, MBBS, DM, FAAN; Maryam Oskoui, MD; Richard Popwell, Jr., MD; Tamara Pringsheim, MD; Alejandro A. Rabinstein, MD, FAAN; Alexander Rae-Grant, MD; Anant Shenoy, MD; Kevin Sheth, MD, FAHA; Kelly Sullivan, PhD; Theresa A. Zesiewicz, MD, FAAN; Jonathan P. Hosey, MD, FAAN (Ex-Officio); Stephen Ashwal, MD, FAAN (Ex-Officio); Deborah Hirtz, MD, FAAN; Jacqueline French, MD, FAAN (Guideline Process Historian)

**Appendix e-2. AANEM Practice Issues Review Panel (PIRP) members**

Yuen T. So, MD, PhD (Co-Chair); Williams S. David, MD, PhD (Co-Chair); Paul E. Barkhaus, MD; Earl J. Craig, MD; Prabhu D. Emmady, MD; Kenneth J. Gaines, MD; James F. Howard, MD; Atul T. Patel, MD; Bharathi Swaminathan, MD; Darrell T. Thomas, MD; Gil I. Wolfe, MD

### Appendix e-3. Complete search strategy

#### *Original Search*

Executed: October 2012

Databases: Medline, EMBASE, Cochrane, and Scopus databases

#### *Cochrane*

EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

#	Searches	Results	Search Type
1	Muscular Dystrophy, Facioscapulohumeral/	7	Advanced
2	facioscapul*.mp.	14	Advanced
3	1 or 2	14	Advanced
4	Muscular Dystrophies/	93	Advanced
5	(FSH or FSHD or FSHMD).mp.	1961	Advanced
6	facioscapul*.mp.	14	Advanced
7	(landouzy* adj2 dejerine*).mp.	0	Advanced
8	or/5-7	1969	Advanced
9	4 and 8	2	Advanced
10	3 or 9	14	Advanced

EBM Reviews - Cochrane Database of Systematic Reviews 2005 to August 2012

#	Searches	Results	Search Type
1	facioscapul*.mp.	10	Advanced
2	(FSH or FSHD or FSHMD).mp.	103	Advanced
3	(landouzy* adj2 dejerine*).mp.	0	Advanced
4	(muscular adj2 dystroph*).mp.	41	Advanced
5	or/1-3	106	Advanced
6	4 and 5	10	Advanced
7	1 or 6	10	Advanced

While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.

*Database of Abstracts of Reviews and Effects*

EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012

#	Searches	Results	Search Type
1	facioscapul*.mp.	0	Advanced
2	(FSH or FSHD or FSHMD).mp.	27	Advanced
3	(landouzy* adj2 dejerine*).mp.	0	Advanced
4	(muscular adj2 dystroph*).mp.	10	Advanced
5	or/1-4	37	Advanced
6	4 and 5	10	Advanced

While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.

*Embase*

*Embase 1974 to 2012 August 27*

#	Searches	Results	Search Type
1	facioscapulohumeral muscular dystrophy/	937	Advanced
2	muscular dystrophy/	13983	Advanced
3	facioscapul*.mp.	1271	Advanced
4	(landouzy* adj2 dejerine*).mp.	59	Advanced
5	(erb adj2 dystroph*).mp.	11	Advanced
6	(erb adj2 syndrome?).mp.	10	Advanced

7	(FSH or FSHD or FSHMD).mp.	34969	Advanced
8	or/3-7	35687	Advanced
9	2 and 8	472	Advanced
10	1 or 9	1221	Advanced
11	(exp animals/ or exp animal experimentation/) not ((exp animals/ or exp animal experimentation/) and exp human/)	2845138	Advanced
12	10 not 11	1206	Advanced
13	limit 12 to yr="2011 -Current"	138	Advanced
14	(2011* or 2012*).em.	1909158	Advanced
15	12 and 14	141	Advanced
16	13 or 15	150	Advanced

*Medline*

Ovid MEDLINE(R) 1946 to August Week 3 2012

#	Searches	Results	Search Type
1	Muscular Dystrophy, Facioscapulohumeral/	414	Advanced
2	Muscular Dystrophies/	12652	Advanced
3	facioscapul*.mp.	834	Advanced
4	(landouzy* adj2 dejerine*).mp.	38	Advanced
5	(FSH or FSHD or FSHMD).mp.	27736	Advanced
6	or/3-5	28110	Advanced
7	2 and 6	394	Advanced
8	1 or 7	787	Advanced
9	exp animals/ not (exp animals/ and exp humans/)	3770988	Advanced
10	8 not 9	779	Advanced
11	limit 10 to yr="2011 -Current"	58	Advanced
12	(2011* or 2012*).em.	1350055	Advanced
13	10 and 12	76	Advanced
14	11 or 13	76	Advanced

While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides



information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.

### *Scopus*

Limited to 2011–2012

Query:

TITLE-ABS-KEY((muscular dystroph\* AND (facioscapul\* OR landouzy\* OR dejerine\* OR (erb W/2 dystroph\*) OR (erb W/2 syndrom\*) OR fsh OR fshd OR fshmd))) AND  
SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR psyc OR soci) AND  
PUBYEAR > 2010 AND PUBYEAR < 2013

Search results: 125 records

While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.

### *Updated Search*

Executed: January 2014

Databases: Medline (via PubMed), and Cochrane

#### *PubMed*

Diagnosis/Broad[filter] AND ("muscular dystrophy, facioscapulohumeral"[MeSH Terms] OR ("muscular"[All Fields] AND "dystrophy"[All Fields] AND "facioscapulohumeral"[All Fields]) OR "facioscapulohumeral muscular dystrophy"[All Fields] OR ("facioscapulohumeral"[All Fields] AND "muscular"[All Fields] AND "dystrophy"[All Fields]) OR "facioscapulohumeral muscular dystrophy"[All Fields])

Therapy/Broad[filter] AND ("muscular dystrophy, facioscapulohumeral"[MeSH Terms] OR ("muscular"[All Fields] AND "dystrophy"[All Fields] AND "facioscapulohumeral"[All Fields]) OR "facioscapulohumeral muscular dystrophy"[All Fields] OR ("facioscapulohumeral"[All

Fields] AND "muscular"[All Fields] AND "dystrophy"[All Fields]) OR "fascioscapulohumeral muscular dystrophy"[All Fields])

## **Appendix e-4. AAN rules for classification of evidence for risk of bias**

### ***For questions related to screening (yield)***

#### *Class I*

- Study of a cohort of patients at risk for the outcome from a defined geographic area (i.e., population based)
- The outcome is objective
- Also required:
  - a. Inclusion criteria defined
  - b. At least 80% of patients undergo the screening of interest

#### *Class II*

- A non–population-based, nonclinical cohort (e.g., mailing list, volunteer panel) or a general medical, neurology clinic/center without a specialized interest in the outcome. Study meets criteria a b (see Class I)
- The outcome is objective

#### *Class III*

- A referral cohort from a center with a potential specialized interest in the outcome

#### *Class IV*

- Did not include persons at risk for the outcome
- Did not statistically sample patients, or patients specifically selected for inclusion by outcome
- Undefined or unaccepted screening procedure or outcome measure
- No measure of frequency or statistical precision calculable

***For questions related to prognostic accuracy***

*Class I*

- Cohort survey with prospective data collection
- Includes a broad spectrum of persons at risk for developing the outcome
- Outcome measurement is objective or determined without knowledge of risk factor status
- Also required:
  - a. Inclusion criteria defined
  - b. At least 80% of enrolled subjects have both the risk factor and outcome measured

*Class II*

- Cohort study with retrospective data collection or case-control study. Study meets criteria a and b (see Class I)
- Includes a broad spectrum of persons with and without the risk factor and the outcome
- The presence of the risk factor and outcome are determined objectively or without knowledge of one another

*Class III*

- Cohort or case-control study
- Narrow spectrum of persons with or without the disease

- The presence of the risk factor and outcome are determined objectively, without knowledge of the other or by different investigators

*Class IV*

- Did not include persons at risk for the outcome
- Did not include patients with and without the risk factor
- Undefined or unaccepted measures of risk factor or outcomes
- No measures of association or statistical precision presented or calculable

***For questions related to therapeutic intervention***

*Class I*

- Randomized, controlled clinical trial (RCT) in a representative population
- Masked or objective outcome assessment
- Relevant baseline characteristics are presented and substantially equivalent between treatment groups, or there is appropriate statistical adjustment for differences
- Also required:
  - a. Concealed allocation
  - b. Primary outcome(s) clearly defined
  - c. Exclusion/inclusion criteria clearly defined
  - d. Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias
  - e. For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required\*:

1. The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority
2. The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose, and dosage adjustments are similar to those previously shown to be effective)
3. The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment
4. The interpretation of the study results is based on a per-protocol analysis that accounts for dropouts or crossovers

### *Class II*

- Cohort study meeting criteria a–e above or an RCT that lacks one or two criteria b–e
- All relevant baseline characteristics are presented and substantially equivalent among treatment groups, or there is appropriate statistical adjustment for differences
- Masked or objective outcome assessment

### *Class III*

- Controlled studies (including studies with external controls such as well-defined natural history controls)

- A description of major confounding differences between treatment groups that could affect outcome\*\*
- Outcome assessment masked, objective, or performed by someone who is not a member of the treatment team

#### *Class IV*

- Did not include patients with the disease
- Did not include patients receiving different interventions
- Undefined or unaccepted interventions or outcome measures
- No measures of effectiveness or statistical precision presented or calculable

\*Numbers 1–3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III

\*\*Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data)

## **Appendix e-5. Steps and rules for formulating recommendations**

### ***Constructing the recommendation and its rationale***

*Rationale for recommendation summarized in the Clinical Context includes three categories of premises*

- Evidence-based conclusions for the systematic review
- Stipulated axiomatic principles of care
- Strong evidence from related conditions not systematically reviewed

*Actionable recommendations include the following mandatory elements*

- The patient population that is the subject of the recommendation
- The person performing the action of the recommendation statement
- The specific action to be performed
- The expected outcome to be attained

### ***Assigning a level of obligation***

*Modal modifiers used to indicate the final level of obligation (LOO)*

- Level A: Must
- Level B: Should
- Level C: Might
- Level U: No recommendation supported

*LOO assigned by eliciting panel members' judgments regarding multiple domains, using a modified Delphi process. Goal is to attain consensus after a maximum of three rounds of voting. Consensus is defined by:*



- $\geq 80\%$  agreement on dichotomous judgments
- $\geq 80\%$  agreement, within one point for ordinal judgments
- If consensus obtained, LOO assigned at the median. If not obtained, LOO assigned at the 10<sup>th</sup> percentile

*Three steps used to assign final LOO*

1. Initial LOO determined by the cogency of the deductive inference supporting the recommendation on the basis of ratings within four domains. Initial LOO anchored to lowest LOO supported by any domain.
  - Confidence in evidence. LOO anchored to confidence in evidence determined by modified form of the Grading of Recommendations Assessment, Development and Evaluation process<sup>e78</sup>
    - Level A: High confidence
    - Level B: Moderate confidence
    - Level C: Low confidence
    - Level U: Very low confidence
  - Soundness of inference assuming all premises are true. LOO anchored to proportion of panel members convinced of soundness of the inference
    - Level A: 100%
    - Level B:  $\geq 80\%$  to  $< 100\%$
    - Level C:  $\geq 50\%$  to  $< 80\%$
    - Level U or R:  $< 50\%$
  - Acceptance of axiomatic principles: LOO anchored to proportion of panel members who accept principles

- Level A: 100%
  - Level B:  $\geq 80\%$  to  $< 100\%$
  - Level C:  $\geq 50\%$  to  $< 80\%$
  - Level U or R:  $< 50\%$
- Belief that evidence cited from related conditions is strong: LOO anchored to proportion of panel members who believe the related evidence is strong
    - Level B:  $\geq 80\%$  to 100% (recommendations dependent on inferences from non-systematically reviewed evidence cannot be anchored to a Level A LOO)
    - Level C:  $\geq 50\%$  to  $< 80\%$
    - Level U or R:  $< 50\%$
2. LOO is modified mandatorily on the basis of the judged magnitude of benefit relative to harm expected to be derived from complying with the recommendation
- Magnitude relative to harm rated on 4-point ordinal scale
    - Large benefit relative to harm: benefit judged large, harm judged none
    - Moderate benefit relative to harm: benefit judged large, harm judged minimal; or benefit judged moderate, harm judged none
    - Small benefit relative to harm: benefit judged large, harm judged moderate; or benefit judged moderate, harm judged minimal; or benefit judged small, harm judged none
    - Benefit to harm judged too close to call: Benefit and harm judged to be the same

- Regardless of cogency of the recommendation the LOO can be no higher than that supported by the rating of the magnitude of benefit relative to harm
    - Level A: Large benefit relative to harm
    - Level B: Moderate benefit relative to harm
    - Level C: Small benefit relative to harm
    - Level U: Too close to call
  - LOO can be increased by one grade if LOO corresponding to benefit relative to harm greater than LOO corresponding to the cogency of the recommendation
3. LOO optionally downgraded on the basis of the following domains
- Importance of the outcome: critical, important, mildly important, not important
  - Expected variation in patient preferences: none, minimal, moderate, large
  - Financial burden relative to benefit expected: none, minimal, moderate, large
  - Availability of intervention: universal, usually, sometimes, limited

## Appendix e-6. Clinical contextual profiles

A1. Clinicians should obtain genetic confirmation of FSHD1 in patients with atypical presentations and no first-degree relatives with genetic confirmation of the disease (Level B).

Strength of Recommendation						
Modifier	R/U	C	B	A	Consensus	
Availability	Limited 0	Sometimes 0	Usually 4	Universal 2	Yes	
Financial burden	Prohibitive 0	Moderate 0	Minimal 5	None 1	Yes	
Variation in preferences	Large 0	Moderate 0	Small 3	Minimal 3	Yes	
Importance of outcomes	Not important 0	Somewhat Imp 0	Very Imp 6	Critical 0	Yes	
Benefit relative to Harm	Too Close 0	Modest 0	Moderate 3	Large 3	Yes	

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	NA
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

B1. Large D4Z4 deletion sizes (contracted D4Z4 allele of 10–20 kb) should alert the clinician that the patient is more likely to develop more significant disability and at an earlier age. Patients with large deletions are also more likely to develop symptomatic extramuscular manifestations (Level B).

Strength of Recommendation						
Modifier	R/U	C	B	A	Consensus	
Availability	Limited 0	Sometimes 0	Usually 4	Universal 2	Yes	
Financial burden	Prohibitive 0	Moderate 0	Minimal 4	None 2	Yes	
Variation in preferences	Large 0	Moderate 1	Small 1	Minimal 4	No	
Importance of outcomes	Not important 0	Somewhat Imp 1	Very Imp 5	Critical 0	Yes	
Benefit relative to Harm	Too Close 0	Modest 2	Moderate 1	Large 3	Yes	

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	N/A
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

C1. Clinicians should obtain baseline pulmonary function tests on all patients with FSHD.

Patients should be monitored regularly if they have abnormal baseline pulmonary function test

results or any combination of severe proximal weakness, kyphoscoliosis, wheelchair dependence, or comorbid conditions that may affect ventilation (e.g., chronic obstructive pulmonary disease, cardiac disease) (Level B).

Strength of Recommendation						
Modifier	R/U	C	B	A	Consensus	
Availability	Limited	0	Sometimes 0	Usually 4	Universal 2	Yes
Financial burden	Prohibitive	0	Moderate 0	Minimal 3	None 3	Yes
Variation in preferences	Large	0	Moderate 0	Small 0	Minimal 6	Yes
Importance of outcomes	Not important	0	Somewhat Imp 1	Very Imp 2	Critical 3	No
Benefit relative to Harm	Too Close	0	Modest 1	Moderate 1	Large 4	Yes

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	x	Yes
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

C2. In patients who have FSHD and compromised pulmonary function studies (e.g., FVC <60%) or symptoms of excessive daytime somnolence or nonrestorative sleep (e.g., frequent nocturnal arousals, morning headaches), clinicians should refer for pulmonary or sleep medicine consultation for consideration of nocturnal sleep monitoring or nocturnal noninvasive ventilation in order to improve QOL (Level B).

Strength of Recommendation						
Modifier	R/U	C	B	A	Consensus	
Availability	Limited	0	Sometimes 1	Usually 3	Universal 2	No
Financial burden	Prohibitive	0	Moderate 0	Minimal 3	None 3	Yes
Variation in preferences	Large	0	Moderate 0	Small 2	Minimal 4	Yes
Importance of outcomes	Not important	0	Somewhat Imp 0	Very Imp 2	Critical 4	Yes
Benefit relative to Harm	Too Close	0	Modest 0	Moderate 2	Large 4	Yes

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	x	Yes
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

C3. Patients with FSHD who do not get regular pulmonary function testing should be tested prior to surgical procedures requiring general anesthesia, as such testing may uncover asymptomatic respiratory compromise (Level B).

Strength of Recommendation						
Modifier	R/U	C	B	A	Consensus	
Availability	Limited	0	Sometimes 0	Usually 2	Universal 4	Yes
Financial burden	Prohibitive	0	Moderate 0	Minimal 4	None 2	Yes
Variation in preferences	Large	0	Moderate 0	Small 0	Minimal 6	Yes
Importance of outcomes	Not important	0	Somewhat Imp 0	Very Imp 3	Critical 3	Yes
Benefit relative to Harm	Too Close	0	Modest 0	Moderate 2	Large 4	Yes

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	x	Yes
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

C4. Patients with FSHD should be referred for cardiac evaluation if they develop overt signs or symptoms of cardiac disease (e.g., shortness of breath, chest pain, palpitations). However, routine cardiac screening is not essential in the absence of cardiac signs or symptoms (Level C).

Strength of Recommendation						
Modifier	R/U	C	B	A	Consensus	
Availability	Limited	0	Sometimes 0	Usually 3	Universal 3	Yes
Financial burden	Prohibitive	0	Moderate 2	Minimal 2	None 2	No
Variation in preferences	Large	0	Moderate 0	Small 4	Minimal 2	Yes
Importance of outcomes	Not important	1	Somewhat Imp 3	Very Imp 2	Critical 0	No
Benefit relative to Harm	Too Close	1	Modest 1	Moderate 3	Large 1	Yes

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	x	NA
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

C5. Clinicians should refer patients with FSHD and large deletions (contracted D4Z4 allele of 10–20 kb) to an experienced ophthalmologist (e.g., retina specialist) for dilated indirect ophthalmoscopy (Level B). The presence and severity of retinal vascular disease at initial screening should be used to determine the frequency of subsequent monitoring (Level B).

Strength of Recommendation

Modifier	R/U	C	B	A	Consensus
Availability	Limited 0	Sometimes 0	Usually 3	Universal 3	Yes
Financial burden	Prohibitive 0	Moderate 1	Minimal 4	None 1	Yes
Variation in preferences	Large 0	Moderate 0	Small 3	Minimal 3	Yes
Importance of outcomes	Not important 0	Somewhat Imp 0	Very Imp 3	Critical 3	Yes
Benefit relative to Harm	Too Close 0	Modest 0	Moderate 3	Large 3	Yes

Strength of Inference

Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	NA
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

C6. Clinicians should screen all young children with FSHD at diagnosis and yearly thereafter until these children start school, as hearing loss may not be present at diagnosis and can be progressive (Level B).

Strength of Recommendation

Modifier	R/U	C	B	A	Consensus
Availability	Limited 0	Sometimes 0	Usually 3	Universal 3	Yes
Financial burden	Prohibitive 0	Moderate 0	Minimal 3	None 3	Yes
Variation in preferences	Large 0	Moderate 0	Small 3	Minimal 3	Yes
Importance of outcomes	Not important 0	Somewhat Imp 0	Very Imp 3	Critical 3	Yes
Benefit relative to Harm	Too Close 0	Modest 0	Moderate 1	Large 5	Yes

Strength of Inference

Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	NA
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

C7. Treating physicians should routinely inquire about pain in patients with FSHD. Referral for a physical therapy evaluation may prove helpful as an initial nonpharmacologic intervention. In patients with persistent pain and no contraindications, a trial of nonsteroidal anti-inflammatory medications is appropriate for acute pain and antidepressants or antiepileptics for chronic pain (Level B).

Strength of Recommendation

Modifier	R/U	C	B	A	Consensus
Availability	Limited 0	Sometimes 0	Usually 1	Universal 5	Yes
Financial burden	Prohibitive 0	Moderate 0	Minimal 4	None 2	Yes
Variation in preferences	Large 0	Moderate 1	Small 2	Minimal 3	No
Importance of outcomes	Not important 0	Somewhat Imp 1	Very Imp 5	Critical 0	Yes
Benefit relative to Harm	Too Close 0	Modest 1	Moderate 3	Large 2	Yes

Strength of Inference

Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	NA
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

D1. In patients with FSHD, clinicians should not prescribe albuterol, corticosteroid, or diltiazem for improving strength (Level B).

Strength of Recommendation

Modifier	R/U	C	B	A	Consensus
Availability	Limited 0	Sometimes 1	Usually 1	Universal 4	No
Financial burden	Prohibitive 0	Moderate 0	Minimal 1	None 5	Yes
Variation in preferences	Large 0	Moderate 0	Small 3	Minimal 3	Yes
Importance of outcomes	Not important 0	Somewhat Imp 2	Very Imp 4	Critical 0	Yes
Benefit relative to Harm	Too Close 0	Modest 0	Moderate 4	Large 2	Yes

Strength of Inference

Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	N/A
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

The author panel judged that even for therapies with only Class IV evidence, the known side effects (e.g., steroids) affected the risk–benefit tradeoff in such a way as to warrant a recommendation against use.

D2. Surgical scapular fixation might be offered cautiously to selected patients after careful consideration of the overall muscle impairment in the involved arm, assessment of potential gain



in range of motion by manual fixation of the scapula, the patient’s rate of disease progression, and the potential adverse consequences of surgery and prolonged postsurgical bracing (Level C).

Strength of Recommendation									
Modifier	R/U		C		B	A	Consensus		
Availability	Limited	0	Sometimes	3	Usually	3	Universal	0	Yes
Financial burden	Prohibitive	0	Moderate	3	Minimal	3	None	0	Yes
Variation in preferences	Large	2	Moderate	3	Small	0	Minimal	1	No
Importance of outcomes	Not important	0	Somewhat Imp	3	Very Imp	3	Critical	0	Yes
Benefit relative to Harm	Too Close	0	Modest	1	Moderate	5	Large	0	Yes

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	N/A
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

D3. Clinicians might encourage patients with FSHD to engage in low-intensity aerobic exercise. An experienced physical therapist can help guide development of individualized exercise programs. Clinicians might also use the practical physical activities guidelines for individuals with disabilities, provided by the US Department of Health and Human Services, when counseling patients about aerobic exercise (Level C).<sup>e76</sup>

Strength of Recommendation									
Modifier	R/U		C		B	A	Consensus		
Availability	Limited	0	Sometimes	0	Usually	2	Universal	4	Yes
Financial burden	Prohibitive	0	Moderate	0	Minimal	5	None	1	Yes
Variation in preferences	Large	1	Moderate	1	Small	3	Minimal	1	No
Importance of outcomes	Not important	0	Somewhat Imp	1	Very Imp	5	Critical	0	Yes
Benefit relative to Harm	Too Close	0	Modest	1	Moderate	4	Large	1	Yes

Strength of Inference					
Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	X	N/A
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

D4. In patients interested in strength training, clinicians may refer patients to physical therapists to establish a safe exercise program using appropriate low/medium weights/resistance that takes into consideration the patients’ physical limitations (Level C).

**Strength of Recommendation**

Modifier	R/U	C	B	A	Consensus
Availability	Limited 0	Sometimes 0	Usually 4	Universal 2	Yes
Financial burden	Prohibitive 0	Moderate 0	Minimal 5	None 1	Yes
Variation in preferences	Large 1	Moderate 2	Small 2	Minimal 1	No
Importance of outcomes	Not important 0	Somewhat Imp 4	Very Imp 2	Critical 0	Yes
Benefit relative to Harm	Too Close 0	Modest 2	Moderate 4	Large 0	Yes

**Strength of Inference**

Element	Weak or N/A	Modest	Moderate	Strong	Consensus
Internal inferences	<50%	≥50% to < 80%	≥80% to < 100%	100%	Yes
Strong related evidence	<50%	≥50% to < 80%	≥80% to 100%	x	N/A
Acceptance of Principles	<50%	≥50% to < 80%	≥80% to < 100%	100%	N/A
Logical	<50%	≥50% to < 80%	≥ 80% to < 100%	100%	Yes
Confidence in Evidence	Very Low	Low	Moderate	High	Yes

## E-REFERENCES

- e1. Padberg GW. Facioscapulohumeral disease. Leiden: University of Leiden; 1982.
- e2. Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. *Neuromuscul Disord* 2001;11:525–529.
- e3. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2006;34:1–15.
- e4. The FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. *Neurology* 1997;48:38–46.
- e5. Stübgen JP, Stipp A. Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment. *J Neurol* 2010;257:1457–1464.
- e6. Wijmenga C, Brouwer OF, Padberg GW, Frants RR. Transmission of de-novo mutation associated with facioscapulohumeral muscular dystrophy. *Lancet* 1992;340:985–986.
- e7. van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. *Hum Mol Genet* 1993;2:2037–2042.
- e8. Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. *Nat Genet* 2002;32:235–236.
- e9. Gabriels J, Beckers MC, Ding H, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. *Gene* 1999;236:25–32.

- e10. Lyle R, Wright TJ, Clark LN, Hewitt JE. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. *Genomics* 1995;28:389–397.
- e11. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* 2010;329:1650–1653.
- e12. Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. *PLoS Genet* 2010;6:e1001181.
- e13. de Greef JC, Lemmers RJ, van Engelen BG, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. *Hum Mutat* 2009;30:1449–1459.
- e14. de Greef JC, Lemmers RJ, Camaño P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. *Neurology* 2010;75:1548–1554.
- e15. Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. *Nat Genet* 2012;44:1370–1374.
- e16. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* 2010;329:1650–1653.
- e17. Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. *Skelet Muscle* 2014;4:12.
- e18. Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 2010;20:471–475.

- e19. Attarian S, Salort-Campana E, Nguyen K, Behin A, Andoni Urtizberea J. Recommendations for the management of facioscapulohumeral muscular dystrophy in 2011. *Rev Neurol (Paris)* 2012;168:910–918.
- e20. Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. *Neurology* 2014;83:1453–1463.
- e21. Kang PB, Morrison L, Iannaccone ST, et al. Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. *Neurology*. In press.
- e22. Padberg GW, Lunt PW, Koch M, Fardeau M. Diagnostic criteria for facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 1991;1:231–234.
- e23. American Academy of Neurology. *Clinical Practice Guidelines Process Manual*, 2004 ed. St. Paul, MN: The American Academy of Neurology; 2004.  
<https://www.aan.com/Guidelines/Home/Development>. Published 2004. Accessed February 12, 2012.
- e24. American Academy of Neurology. *Clinical Practice Guidelines Process Manual*, 2011 ed. St. Paul, MN: The American Academy of Neurology; 2011.  
<https://www.aan.com/Guidelines/Home/Development>. Published August 2011. Accessed February 12, 2012.

- e25. Hsu YD, Kao MC, Shyu WC, et al. Application of chromosome 4q35-qter marker (pFR-1) for DNA rearrangement of facioscapulohumeral muscular dystrophy patients in Taiwan. *J Neurol Sci* 1997;149:73–79.
- e26. Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. *Neurology* 1998;50:1791–1794.
- e27. Zeng Y, Zhang C, Su Q. Gene diagnosis of facioscapulohumeral muscular dystrophy [in Chinese]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2001;18:213–215.
- e28. Goto K, Lee JH, Matsuda C, et al. DNA rearrangements in Japanese facioscapulohumeral muscular dystrophy patients: clinical correlations. *Neuromuscul Disord* 1995;5:201–208.
- e29. Scionti I, Greco F, Ricci G, et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of facioscapulohumeral muscular dystrophy. *Am J Hum Genet* 2012;90:628–635.
- e30. Ricci E, Galluzzi G, Deidda G, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. *Ann Neurol* 1999;45:751–757.
- e31. Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. *Am J Hum Genet* 2007;81:884–894.
- e32. Spurlock G, Jim HP, Upadhyaya M. Confirmation that the specific SSLP microsatellite allele 4qA161 segregates with facioscapulohumeral muscular dystrophy (FSHD) in a cohort of multiplex and simplex FSHD families. *Muscle Nerve* 2010;42:820–821.

- e33. Köhler J, Röhrig D, Bathke KD, Koch MC. Evaluation of the facioscapulohumeral muscular dystrophy (FSHD1) phenotype in correlation to the concurrence of 4q35 and 10q26 fragments. *Clin Genet* 1999;55:88–94.
- e34. Lunt PW, Jardine PE, Koch M, et al. Phenotypic-genotypic correlation will assist genetic counseling in 4q35-facioscapulohumeral muscular dystrophy. *Muscle Nerve Suppl* 1995;2:S103–S109.
- e35. Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. *Ann Neurol* 1996;39:744–748.
- e36. Kilmer DD, Abresch RT, McCrory MA, et al. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. *Am J Phys Med Rehabil* 1995;74(5 Suppl):S131–S139.
- e37. Padua L, Aprile I, Frusciante R, et al. Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2009;40:200–205.
- e38. Statland JM, Tawil R. Risk of functional impairment in facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2014;49:520–527.
- e39. Sakellariou P, Kekou K, Fryssira H, et al. Mutation spectrum and phenotypic manifestation in FSHD Greek patients. *Neuromuscul Disord* 2012;22:339–349.
- e40. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. *Neurology* 2004;63:176–178.
- e41. Stübgen JP, Schultz C. Lung and respiratory muscle function in facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2009;39:729–734.

- e42. de Visser M, de Voogt WG, la Rivière GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. *Muscle Nerve* 1992;15:591–596.
- e43. Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. *J Am Coll Cardiol* 1990;15:292–299.
- e44. Galetta F, Franzoni F, Sposito R, et al. Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 2005;15:403–408.
- e45. Trevisan CP, Pastorello E, Armani M, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. *Eur Neurol* 2006;56:1–5.
- e46. Laforêt P, de Toma C, Eymard B, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. *Neurology* 1998;51:1454–1456.
- e47. Nakagawa M, Matsuzaki T, Higuchi I, et al. Facioscapulohumeral muscular dystrophy: clinical diversity and genetic abnormalities in Japanese patients. *Intern Med* 1997;36:333–339.
- e48. Padberg GW, Brouwer OF, de Keizer RJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. *Muscle Nerve Suppl* 1995;2:S73–S80.
- e49. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. *Brain* 1987;110:631–648.



- e50. Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. *Neurology* 2013;80:1247–1250.
- e51. Trevisan CP, Pastorello E, Ermani M, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. *Audiol Neurootol* 2008;13:1–6.
- e52. Rogers MT, Zhao F, Harper PS, Stephens D. Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 2002;12:358–365.
- e53. Lutz KL, Holte L, Kliethermes SA, Stephan C, Mathews KD. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. *Neurology* 2013;81:1374–1377.
- e54. Jensen MP, Hoffman AJ, Stoelb BL, Abresch RT, Carter GT, McDonald CM. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. *Arch Phys Med Rehabil* 2008;89:320–328.
- e55. Guy-Coichard C, Nguyen DT, Delorme T, Boureau F. Pain in hereditary neuromuscular disorders and myasthenia gravis: a national survey of frequency, characteristics, and impact. *J Pain Symptom Manage* 2008;35:40–50.
- e56. van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. *Neurology* 2004;63:702–708.
- e57. Kissel JT, McDermott MP, Mendell JR, et al; FSH-DY Group. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. *Neurology* 2001;57:1434–1440.
- e58. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. *Ann Neurol* 2008;63:561–571.

- e59. van der Kooi EL, Kalkman JS, Lindeman E, et al. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. *J Neurol* 2007;254:931–940.
- e60. Tawil R, McDermott MP, Pandya S, et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. *Neurology* 1997;48:46–49.
- e61. Elsheikh BH, Bollman E, Peruggia M, King W, Galloway G, Kissel JT. Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy. *Neurology* 2007;68:1428–1429.
- e62. Copeland SA, Levy O, Warner GC, Dodenhoff RM. The shoulder in patients with muscular dystrophy. *Clin Orthop Relat Res* 1999;(368):80–91.
- e63. Rhee YG, Ha JH. Long-term results of scapulothoracic arthrodesis of facioscapulohumeral muscular dystrophy. *J Shoulder Elbow Surg* 2006;15:445–450.
- e64. Diab M, Darras BT, Shapiro F. Scapulothoracic fusion for facioscapulohumeral muscular dystrophy. *J Bone Joint Surg Am* 2005;87:2267–2275.
- e65. Krishnan SG, Hawkins RJ, Michelotti JD, Litchfield R, Willis RB, Kim YK. Scapulothoracic arthrodesis: indications, technique, and results. *Clin Orthop Relat Res* 2005;(435):126–133.
- e66. Jakab E, Gledhill RB. Simplified technique for scapulocostal fusion in facioscapulohumeral dystrophy. *J Pediatr Orthop* 1993;13:749–751.
- e67. Andrews CT, Taylor TC, Patterson VH. Scapulothoracic arthrodesis for patients with facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 1998;8:580–584.
- e68. Giannini S, Faldini C, Pagkrati S, et al. Fixation of winged scapula in facioscapulohumeral muscular dystrophy. *Clin Med Res* 2007;5:155–162.

- e69. Giannini S, Ceccarelli F, Faldini C, Pagkrati S, Merlini L. Scapulopexy of winged scapula secondary to facioscapulohumeral muscular dystrophy. *Clin Orthop Relat Res* 2006;449:288–294.
- e70. Demirhan M, Uysal O, Atalar AC, Kilicoglu O, Serdaroglu P. Scapulothoracic arthrodesis in facioscapulohumeral dystrophy with multifilament cable. *Clin Orthop Relat Res* 2009;467:2090–2097.
- e71. Bunch WH, Siegel IM. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy. Review of seventeen procedures with three to twenty-one-year follow-up. *J Bone Joint Surg Am* 1993;75:372–376.
- e72. Berne D, Laude F, Laporte C, Fardeau M, Sillant G. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy. *Clin Orthop Relat Res* 2003;409:106–113.
- e73. Olsen DB, Ørngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. *Neurology* 2005;64:1064–1066.
- e74. Ambrosino N, Carpenè N, Gherardi M. Chronic respiratory care for neuromuscular diseases in adults. *Eur Respir J* 2009;34:444–451.
- e75. Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts AC. Strength training and aerobic exercise training for muscle disease. *Cochrane Database Syst Rev* 2013;7:CD003907.
- e76. US Department of Health and Human Services Office of Disease Prevention and Health Promotion. Additional Considerations for Some Adults. In: *Physical Activity Guidelines for Americans;chap 7*. <http://www.health.gov/paguidelines/guidelines/chapter7.aspx>. Published September 2008. Accessed October 1, 2012.

- e77. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; for the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61:344–349.
- e78. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol* 2011;64:380–382.

**Evidence-based Guideline Summary: Evaluation, Diagnosis, and Management of  
Facioscapulohumeral Muscular Dystrophy**

Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine

Rabi Tawil, MD, FAAN<sup>1</sup>; John T. Kissel, MD, FAAN<sup>2</sup>; Chad Heatwole, MD, MS-CI<sup>3</sup>; Shree Pandya, PT, DPT, MS<sup>4</sup>; Gary Gronseth, MD, FAAN<sup>5</sup>; Michael Benatar, MBChB, DPhil, FAAN<sup>6</sup>

(1) MDA Neuromuscular Disease Clinic, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

(2) Department of Neurology, Wexner Medical Center, Ohio State University, Columbus, OH

(3) Department of Neurology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

(4) Department of Neurology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

(5) Department of Neurology, University of Kansas School of Medicine, Kansas City, KS

(6) Department of Neurology, Miller School of Medicine, University of Miami, Miami, OH

Correspondence to

American Academy of Neurology:

[guidelines@aan.com](mailto:guidelines@aan.com)

Title character count: 113

Abstract word count: 243

**Confidential: Not for duplication, dissemination, or citation.**

Manuscript word count: 3500

Approved by the Guideline Development, Dissemination, and Implementation Subcommittee on July 23, 2014; by the AAN Practice Committee on October 20, 2014; by the AANEM Board of Directors on [date]; and by the AANI Board of Directors on [date].

**This guideline was endorsed by the FSH Society on December 18, 2014.**

## **AUTHOR CONTRIBUTIONS**

Rabi Tawil: study concept and design, acquisition of data, analysis or interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content, study supervision.

John Kissel: acquisition of data, analysis or interpretation of data, critical revision of the manuscript for important intellectual content.

Chad Heatwole: acquisition of data, analysis or interpretation of data, critical revision of the manuscript for important intellectual content.

Shree Pandya: acquisition of data, analysis or interpretation of data, critical revision of the manuscript for important intellectual content.

Gary Gronseth: study concept and design, acquisition of data, analysis or interpretation of data, study supervision.

Michael Benatar: study concept and design, acquisition of data, analysis or interpretation of data, drafting/revising the manuscript, critical revision of the manuscript for important intellectual content, study supervision.

## **STUDY FUNDING**

Funding for this publication was made possible (in part) by grant DD10-1012 from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The remaining funding was provided by the American Academy of Neurology.

## **DISCLOSURE**

Dr. Tawil has served as a consultant for aTyr Pharma, Cytokinetics Inc., and Novartis; and received research funding support from the National Institutes of Health (NIH) and the FSH Society.

Dr. Kissel served on a scientific advisory board for and received travel funding from Cytokinetics.

Dr. Heatwole receives research funding support from the NIH and the New York State Empire Clinical Research Investigator Program.

Dr. Pandya reports no relevant disclosures.

Dr. Gronseth reports no relevant disclosures.

Dr. Benatar reports no relevant disclosures.



## **ABBREVIATIONS**

AAN: American Academy of Neurology

AANEM: American Association of the Neuromuscular & Electrodiagnostic Medicine

CI: confidence interval

*DUX4*: double homeobox 4

FSHD: facioscapulohumeral muscular dystrophy

FSHD1: FSHD type 1

FSHD2: FSHD type 2

GDDI: Guideline Development, Dissemination, and Implementation Subcommittee

kb: kilobase

MD: muscular dystrophy

MYO-029: myostatin inhibitor

PIRP: Practice Issues Review Panel

poly-A: polyadenylation

QOL: quality of life

## **ABSTRACT**

**Objective:** To develop recommendations for the evaluation, diagnosis, prognostication, and treatment of facioscapulohumeral muscular dystrophy (FSHD) from a systematic review and analysis of the evidence.

**Methods:** Relevant articles were analyzed in accordance with the American Academy of Neurology classification of evidence schemes for diagnostic, prognostic, and treatment studies. Recommendations were linked to the strength of the evidence and other factors.

**Results and recommendations:** Available genetic testing for FSHD type 1 is highly sensitive and specific. Although respiratory insufficiency occurs rarely in FSHD, patients with severe FSHD should have routine pulmonary function testing. Routine cardiac screening is not necessary in patients with FSHD without cardiac symptoms. Symptomatic retinal vascular disease is very rare in FSHD. Exudative retinopathy, however, is potentially preventable, and patients with large deletions should be screened through dilated indirect ophthalmoscopy. The prevalence of clinically relevant hearing loss is not clear. In clinical practice, patients with childhood-onset FSHD may have significant hearing loss. Because undetected hearing loss may impair language development, screening through audiometry is recommended for such patients. Musculoskeletal pain is common in FSHD and treating physicians should routinely inquire about pain. There is at present no effective pharmacologic intervention in FSHD. Available studies suggest that scapular fixation is safe and effective. Surgical scapular fixation might be cautiously offered to selected patients. Aerobic exercise in FSHD appears to be safe and potentially beneficial. On the basis of the evidence, patients with FSHD might be encouraged to engage in low-intensity aerobic exercises.

## **INTRODUCTION**

This document summarizes extensive information provided in the complete guideline, available as a data supplement on the *Neurology*<sup>®</sup> Web site (Neurology.org). Appendices e-1 through e-6 are available in the complete guideline document; references e1 through e35, cited herein, are available at Neurology.org.

Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of muscular dystrophy (MD), with a prevalence of approximately 1:15,000–1:20,000.<sup>1,2</sup> It is an autosomal dominant disorder; however, up to 30% of cases are sporadic, arising from de novo mutations.

FSHD symptoms typically develop in the second decade of life but can begin at any age from infancy to late adulthood.<sup>1</sup> FSHD is characterized by a distinctive, initially regional distribution of muscle involvement. Facial, periscapular, and humeral muscles typically are involved early in the disease course, although the deltoids are spared.<sup>3</sup> FSHD typically progresses slowly but variably.<sup>4,5</sup> About 20% of individuals with FSHD become wheelchair dependent after age 50.<sup>1</sup>

Extramuscular manifestations occur in FSHD and can include respiratory compromise; retinal vascular disease that, rarely, leads to exudative retinopathy and visual loss; hearing loss; and, possibly, increased incidence of cardiac arrhythmias.

The molecular genetic basis of FSHD is complex. At the tip of chromosome 4q35 lies a repetitive 3.3 kilobase (kb) DNA sequence known as D4Z4 repeats.<sup>6,7</sup> Moreover, there are 2

different DNA variants distal to the D4Z4 repeats, called the A and B allelic variants.<sup>8</sup> FSHD type 1 (FSHD1), accounting for 95% of FSHD cases, results from deletion of a critical number of D4Z4 repeats, but only when this occurs on the A allele. The biological basis for this dual requirement is becoming increasingly understood. Contraction of the D4Z4 repeat results in a more open chromatin structure, allowing the potential expression of gene sequences within the repeats. One such gene, double homeobox 4 (*DUX4*), lacks the polyadenylation (poly-A) sequence required to produce stable messenger RNA.<sup>9,10</sup> Because only the A (not the B) allele variant contains a poly-A sequence, stable *DUX4* expression can occur only in the presence of the A allelic variant.<sup>11,12</sup>

Complicating matters is the existence of a genetically distinct but clinically identical FSHD type—FSHD type 2 (FSHD2)—now known to account for approximately 5% of patients with clinically defined FSHD.<sup>13,14</sup> Unlike the majority of patients with FSHD (i.e., FSHD1), patients with FSHD2 do not have contractions in the 4q35 D4Z4. As with FSHD1, and despite a normal number of repeats, the chromatin structure at the D4Z4 repeats is more open, and at least one 4q35 allele is an A variant.<sup>13</sup> Recent studies have implicated mutations in *SMCHD1*, a gene on chromosome 18 that functions as a chromatin modifier, as the cause of the D4Z4 chromatin changes observed in about 85% of patients with FSHD2.<sup>15</sup> Comprehensive molecular genetic testing for FSHD2 is complex and not readily available currently, and thus is not addressed herein.

Despite having distinct genotypes, FSHD1 and FSHD2 have an identical molecular basis that results from the aberrant expression of the *DUX4* gene in skeletal muscle.<sup>15,16</sup> *DUX4* protein is a

transcription factor normally expressed only in the germline, but little is known about its function.<sup>17</sup> Preliminary evidence suggests that inappropriate expression of DUX4 and its transcriptional targets in skeletal muscle can result in apoptosis, impaired muscle regeneration, and induction of an immune response.<sup>17</sup>

Previous FSHD practice guidelines have been based on expert opinion.<sup>18,19</sup> The present guideline, based on systematic review of the evidence, focuses exclusively on FSHD. Duchenne MD and myotonic dystrophy will be discussed in forthcoming guidelines; limb-girdle MD and congenital MD are addressed in separate guidelines.<sup>20,21</sup> The present guideline addresses the following practical issues related to FSHD (reflective only of evidence relevant to FSHD1; no large FSHD2 clinical studies exist):

1. For patients with clinically defined FSHD (as determined by explicitly stated clinical criteria substantially similar to the consortium criteria),<sup>22</sup> how often does D4Z4 contraction on 4q35 confirm diagnosis of FSHD (irrespective of presence of allele A)? For individuals who do not have FSHD, how often is a D4Z4 contraction on 4q35 found, and how often is a D4Z4 contraction on 4q35 on allele A found?
2. Which factors are associated with or predict loss of clinically meaningful milestones (e.g., loss of independent ambulation)?
3. How frequent are respiratory abnormalities, cardiac abnormalities, retinal disease, hearing loss, and pain?
4. Do interventions (as compared with no intervention) improve patient-relevant outcomes? Are there features that identify patients who are more or less likely to improve with a specific intervention?

## **DESCRIPTION OF THE ANALYTIC PROCESS**

The methods used to develop this guideline are detailed in the complete guideline (see online data supplement). In brief, the AAN convened an author panel of clinicians with FSHD expertise. The panel systematically reviewed the evidence relevant to the posed questions according to the processes described in the 2004 and 2011 AAN process manuals.<sup>23,24</sup> The panel formulated practice recommendations based on the evidence systematically reviewed, stipulated axiomatic principles of care, strong evidence from closely related conditions, and judgments regarding risk–benefit and patient preferences.

## **ANALYSIS OF EVIDENCE**

### **FSHD genetic testing.**

Understanding the molecular genetics of FSHD1 is critical to molecular diagnosis of this disorder. Healthy individuals possess at least 11 D4Z4 repeats, yielding a DNA fragment >38 kb on standard genetic testing. Affected individuals, in contrast, possess 1–10 repeats, yielding DNA fragments 10–38 kb in size.<sup>7</sup> Measurement of the size of the residual D4Z4 sequence on 4q35 forms the basis for genetic testing in FSHD. As previously discussed, FSHD identification also requires that the contraction occur on the A allelic variant. Routine first-pass commercial genetic testing in the United States measures the residual D4Z4 repeat sizes without determining the A or B allelic variants. The prevalence of D4Z4 repeat sizes ranging from 1–10 alleles is low in the general population. This low prevalence raises questions about the clinical utility of routine determination of the A/B variant in molecular confirmation of FSHD.

Our systematic review identified 9 Class III studies<sup>25–33</sup> from specialty clinics that, together, demonstrate that the finding of a D4Z4 contraction on chromosome 4q35 likely has a sensitivity of 93% and a specificity of 98% for diagnosis of clinically defined FSHD. In a patient population with clinically defined FSHD, the degree of specificity is unlikely to be further enhanced by testing for presence of the A variant.

**Risk factors for disease severity.**

In any neuromuscular disorder, a critical aspect of patient management lies in identifying clinical, biochemical, or genetic aspects of the illness associated with prognosis. It is indispensable to identify such risk factors that might be linked to a severe (or more benign) course when discussing prognosis with patients, designing therapy programs and other meaningful interventions, and helping patients make important medical, financial, and other life decisions. This is true particularly in a disease such as FSHD where extent and severity of involvement vary tremendously.

***D4Z4 repeat size.*** The systematic review identified one Class I study<sup>34</sup> demonstrating that in patients with FSHD, smaller D4Z4 repeat size is probably associated with more severe disease as measured by age at diagnosis and age at wheelchair dependence. Class II and Class III studies<sup>30,35–37</sup> provided evidence that smaller fragment size is possibly associated with other measures of disease severity, including early age at onset, quantitative computerized muscle testing, severity of leg weakness, global severity scores, and earlier loss of ambulation.

**Age at onset.** One Class III study<sup>35</sup> demonstrated that earlier age at onset appears to be associated with earlier loss of ambulation (as well as smaller fragment size).

### **Complications.**

Although the cardinal features of FSHD involve limb weakness that starts with focal weakness of the shoulders, face, and humeral muscles, additional systemic features may occur. These extramuscular features may have significant and, at times, life-threatening consequences.

**Respiratory abnormalities.** Evidence from one Class II study<sup>38</sup> and one Class III study<sup>39</sup> suggests that respiratory insufficiency and reduced pulmonary function may occur, with estimated frequencies varying from 1.25% (95% confidence interval [CI] 0.5%–2%) to 13% (95% CI 0.7%–27%). Given the imprecision of these estimates and the quality of the evidence, we cannot reliably estimate the frequency and severity of respiratory compromise in patients with FSHD.

**Cardiac abnormalities.** Four Class III electrocardiographic/echocardiographic studies found no structural abnormalities in 80 patients with FSHD (95% CI 0%–4.6%),<sup>40–e3</sup> indicating that the frequency of structural cardiac abnormalities on electrocardiography/echocardiography may be low. Six Class III studies examining the frequency of symptomatic or inducible supraventricular arrhythmias in patients with FSHD<sup>39–e4</sup> found these arrhythmias in 9.7% (95% CI 6.5%–14.2%). Because of risk of referral bias in these studies, data are insufficient to reliably determine the frequency of clinically relevant cardiac abnormalities.



**Retinal vascular disease.** The combined results from 4 Class III studies<sup>e5–e8</sup> demonstrated that up to 25% (95% CI 20.9%–30.8%) of patients with FSHD had abnormalities on retinal examination and 0.6% (95% CI 0.2%–1.5%) had symptomatic retinal disease.

**Hearing loss.** Eight Class III studies using audiometry to examine hearing demonstrated that 15.5% (95% CI 12.1%–19.4%) had audiometric abnormalities.<sup>26,33,e6–e11</sup> In addition, hearing loss occurs only in patients with large deletions ( $\leq 20$  kb); 32% (95% CI 16.7%–51.4%) of patients in this group have hearing loss.<sup>e11</sup> Confidence in the evidence for prevalence of audiometric abnormalities is very low due to the wide range of frequencies.

**Pain.** One Class II study and 2 Class III studies<sup>e12–e14</sup> observed that up to 79% (95% CI 74.6%–82.8%) of patients with FSHD complained of pain. The most common sites of pain are, in descending order, the lower back, the legs, the shoulders, and the neck.<sup>e13</sup> A single Class III study assessing pain severity noted that 10.8% (95% CI 3.2%–18.3%) of patients had clinically significant pain.<sup>e12</sup>

### **Treatment.**

The goal of therapy in FSHD is to improve muscle strength or function, or both. Until recently the underlying pathophysiology of FSHD was unknown, and thus pharmacologic trials have focused on improving muscle mass and strength, whereas surgical studies of scapular fixation have been motivated by efforts to improve function notwithstanding the presence of weakness.

***Pharmacologic interventions.*** Based on 2 Class I studies examining the effect of oral albuterol on strength in FSHD,<sup>e15,e16</sup> it is highly likely that albuterol is ineffective for improving muscle strength. Data are insufficient to judge the efficacy of albuterol for muscle pain and fatigue.<sup>e17</sup>

A Class I study of the effect of an IV myostatin inhibitor (MYO-029) demonstrated no significant improvement in muscle strength.<sup>e18</sup>

Data are insufficient to support or refute the effects of prednisone (1 Class IV study)<sup>e19</sup> or diltiazem (1 Class IV study)<sup>e20</sup> on muscle strength.

***Surgical scapular fixation.*** One Class III study and 10 Class IV uncontrolled case series<sup>e21-e31</sup> used different surgical approaches and demonstrated consistent responses on measures of shoulder function to scapular fixation. These studies indicated that scapular fixation is possibly effective for improving shoulder abduction and anterior flexion.

***Exercise.*** One Class I study examining the effect of strength training on muscle strength demonstrated no evidence of improved isometric strength testing; however, it reported improvement of significant but questionable importance in dynamic strength in 1 of 2 muscle groups tested.<sup>e17</sup> This study supported the conclusion that strength-training exercise is probably ineffective for improving muscle strength meaningfully.

A single Class III study<sup>e32</sup> provided very weak evidence that low-intensity aerobic exercise improved both workload (by 17%; standard deviation 4,  $p < 0.002$ ) and self-reported levels of activity, without evidence of muscle damage.

## **PRACTICE RECOMMENDATIONS**

The recommendations below encompass four major areas: diagnosis, predictors of severity, surveillance for complications, and treatment. A clinical context section precedes each recommendation, and outlines the evidence, general principles of care, and evidence from related disorders that inform the recommendations.

### **Diagnosis of FSHD.**

See also the algorithm in figure 1.

**Clinical context.** When clinical presentation of FSHD is typical and the inheritance pattern is consistent with autosomal dominant inheritance, clinical diagnosis is usually straightforward. If, in such circumstances, the diagnosis is genetically confirmed in a first-degree relative, genetic testing is not necessary for each affected individual. However, atypical presentations are not uncommon. In the setting of atypical or sporadic cases, genetic confirmation is important for genetic counseling, especially with the recent discovery of 2 genetically distinct forms of FSHD.

In the most common FSHD type, FSHD1, disease results from contraction of a DNA repeat sequence, termed *D4Z4 repeat*, on one copy of 4q35 from >10 repeats to 1–10 repeats. In addition, the contraction must occur in the presence of one particular (A variant) of 2 (A/B) sequence variants distal to the repeats. Available molecular testing for FSHD1, which measures

**Confidential: Not for duplication, dissemination, or citation.**

only the presence of a repeat contraction on initial testing, is highly sensitive and specific. In studies that utilized strict diagnostic criteria for FSHD, determining whether a contraction occurs on an A variant genetic background does not appear to improve diagnostic specificity. However, in clinical practice, strict clinical diagnostic criteria might not be adhered to, increasing the chances of a false-positive result. In consequence, determining that a D4Z4 contraction is occurring on an A variant is warranted when the clinical presentation is atypical for FSHD. At present, commercial genetic testing in FSHD is limited to FSHD1 testing.

***Recommendation.***

Clinicians should obtain genetic confirmation of FSHD1 in patients with atypical presentations and no first-degree relatives with genetic confirmation of the disease (Level B). Figure 1 shows the recommended FSHD molecular diagnosis decision tree.

**Predictors of severity in FSHD.**

***Clinical context.*** Factors that predict disease severity in FSHD are important for counseling patients and for screening for and managing potential complications. The D4Z4 deletion size appears to be somewhat predictive of the overall rate of disease progression. D4Z4 deletion size should be used cautiously for predicting disease progression rate in any particular individual due to other sources of variation affecting disease severity, including intrafamilial factors. Clinical experience suggests that patients with severe childhood-onset disease almost invariably have very large deletions (i.e., contracted D4Z4 allele of 10–20 kb or 1–4 repeats), suggesting a much more robust correlation between disease severity and large deletions.

***Recommendation.***

Large D4Z4 deletion sizes (contracted D4Z4 allele of 10–20 kb) should alert the clinician that the patient is more likely to develop more significant disability and at an earlier age. Patients with large deletions are also more likely to develop symptomatic extramuscular manifestations (Level B). (See next section on monitoring for FSHD complications.)

**Monitoring for complications of FSHD.**

***Pulmonary complications.***

*Clinical context.* Our systematic review revealed that some patients with FSHD develop respiratory muscle weakness that can result in respiratory failure and need for mechanical ventilator assistance (e.g., nocturnal bilevel positive airway pressure), although this complication is uncommon. Patients with chronic respiratory failure from neuromuscular-related weakness often do not have classic symptoms of ventilatory failure (i.e., overt dyspnea). Impending respiratory failure, therefore, may begin with respiratory insufficiency mainly during sleep, resulting in excessive daytime somnolence or nonrestorative sleep. Respiratory insufficiency in patients with FSHD, therefore, may be evident only through pulmonary function testing. Respiratory failure constitutes a major source of morbidity in patients with most MD types and can severely disrupt sleeping, daily activities, and quality of life (QOL). Early intervention with noninvasive mechanical ventilation leads to improved survival and QOL.<sup>e33</sup>

***Recommendations.***

Clinicians should obtain baseline pulmonary function tests on all patients with FSHD. Patients should be monitored regularly if they have abnormal baseline pulmonary function test results or

**Confidential: Not for duplication, dissemination, or citation.**

any combination of severe proximal weakness, kyphoscoliosis, wheelchair dependence, or comorbid conditions that may affect ventilation (e.g., chronic obstructive pulmonary disease, cardiac disease) (Level B).

In patients who have FSHD and either 1) compromised pulmonary function studies (e.g., forced vital capacity <60%) or 2) symptoms of excessive daytime somnolence or nonrestorative sleep (e.g., frequent nocturnal arousals, morning headaches), clinicians should refer patients for pulmonary or sleep medicine consultation for consideration of nocturnal sleep monitoring or nocturnal noninvasive ventilation in order to improve QOL (Level B).

Patients with FSHD who do not get regular pulmonary function testing should be tested prior to surgical procedures requiring general anesthesia, as such testing may uncover asymptomatic respiratory compromise (Level B).

### ***Cardiac abnormalities.***

*Clinical context.* Our systematic review revealed very little evidence for structural cardiac abnormalities in FSHD. Also, data are insufficient to suggest that patients with FSHD are susceptible to cardiac arrhythmias. Routine electrocardiographic/echocardiographic testing is therefore unnecessary in patients with FSHD who are asymptomatic.

### ***Recommendation.***

Patients with FSHD should be referred for cardiac evaluation if they develop overt signs or symptoms of cardiac disease (e.g., shortness of breath, chest pain, palpitations). However, routine cardiac screening is not essential in the absence of cardiac signs or symptoms (Level C).

***Retinal vascular disease.***

*Clinical context.* Our systematic review suggests that symptomatic retinal vascular disease in the form of an exudative retinopathy (Coats disease) is very rare in FSHD but tends to affect patients with large deletions almost exclusively. Untreated exudative retinopathy can lead to significant visual loss, which may be prevented by early intervention.

***Recommendation.***

Clinicians should refer patients with FSHD and large deletions (contracted D4Z4 allele of 10–20 kb) to an experienced ophthalmologist (e.g., retina specialist) for dilated indirect ophthalmoscopy (Level B). The presence and severity of retinal vascular disease at initial screening should be used to determine the frequency of subsequent monitoring (Level B).

***Hearing loss.***

*Clinical context.* Our systematic review shows that the available studies fail to capture the prevalence and clinical relevance of hearing loss in FSHD. In clinical practice, most patients with FSHD and hearing loss requiring the use of a hearing aid have childhood-onset FSHD with large D4Z4 deletions. Two recent studies support this clinical impression. Moreover, one of the studies suggests that hearing loss is progressive in some patients. Adults and older children are cognizant of the hearing loss onset, and therefore intervention can occur early when required.

**Confidential: Not for duplication, dissemination, or citation.**

However, failure to detect hearing loss in infants and younger children may significantly delay or impair language development.

*Recommendation.*

Clinicians should screen all young children with FSHD at diagnosis and yearly thereafter until these children start school, as hearing loss may not be present at diagnosis and can be progressive (Level B).

***Pain.***

*Clinical context.* Pain is a common complaint in FSHD and appears to be mostly musculoskeletal in origin. Pain compounding muscle weakness can have a significant impact on QOL. Physical therapists often can provide insight into the mechanism of pain in patients with weakness. Nonsteroidal anti-inflammatory medications are useful for acute pain, and antidepressants or antiepileptics, for chronic musculoskeletal pain.

*Recommendation.*

Treating physicians should routinely inquire about pain in patients with FSHD. Referral for a physical therapy evaluation may prove helpful as an initial nonpharmacologic intervention. In patients with persistent pain and no contraindications, a trial of nonsteroidal anti-inflammatory medications is appropriate for acute pain and antidepressants or antiepileptics for chronic pain (Level B).

**Treatment of FSHD.**



***Pharmacologic interventions.***

*Clinical context.* As of this writing, no evidence exists for any effective pharmacologic interventions that improve strength or slow disease progression in FSHD. Randomized, controlled trials of albuterol were negative. Uncontrolled, open-label trials of corticosteroid and diltiazem showed no benefit. A controlled early phase II study of MYO-029, a myostatin inhibitor, also failed to show benefit.

***Recommendation.***

In patients with FSHD, clinicians should not prescribe albuterol, corticosteroid, or diltiazem for improving strength (Level B).

***Surgical scapular fixation.***

*Clinical context.* In patients with FSHD, limited shoulder range of motion due to periscapular muscle weakness is a major source of functional limitation. Moreover, in many patients, bedside manual scapular fixation can result in significant improvement in shoulder range of motion. Postoperative complications are infrequent but include hemo- or pneumothorax, pain, infection, non-union, and reduced lung capacity. Scapular fixation appears to be generally safe and may be effective for improving shoulder range of motion.

***Recommendation.***

Surgical scapular fixation might be offered cautiously to selected patients after careful consideration of the overall muscle impairment in the involved arm, assessment of potential gain

in range of motion by manual fixation of the scapula, the patient's rate of disease progression, and the potential adverse consequences of surgery and prolonged postsurgical bracing (Level C).

***Aerobic exercise.***

*Clinical context.* Aerobic exercise in FSHD appears to be safe and potentially beneficial, as has been shown in many other muscle diseases.<sup>e34</sup> Aerobic fitness is important for overall health. To minimize injury from falls or overuse, the type of aerobic exercise should be tailored to the patient's particular distribution of weakness. For example, a stationary bicycle rather than a treadmill should be recommended for patients with leg weakness. Although no data exist to suggest that strength training is detrimental in FSHD, further research is needed to determine whether such strength training will result in clinically meaningful long-term functional improvement.

***Recommendations.***

Clinicians might encourage patients with FSHD to engage in low-intensity aerobic exercise. An experienced physical therapist can help guide development of individualized exercise programs. Clinicians might also use the practical physical activities guidelines for individuals with disabilities, provided by the US Department of Health and Human Services, when counseling patients about aerobic exercise (Level C).<sup>e35</sup>

In patients interested in strength training, clinicians may refer patients to physical therapists to establish a safe exercise program using appropriate low/medium weights/resistance that takes into consideration the patients' physical limitations (Level C).

**Confidential: Not for duplication, dissemination, or citation.**

## **DISCLAIMER**

Clinical practice guidelines, practice advisories, systematic reviews and other guidance published by the American Academy of Neurology and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information: 1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; 2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); 3) addresses only the question(s) specifically identified; 4) does not mandate any particular course of medical care; and 5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. AAN provides this information on an “as is” basis, and makes no warranty, expressed or implied, regarding the information. AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.


## **CONFLICT OF INTEREST**

The American Academy of Neurology and American Association of Neuromuscular & Electrodiagnostic Medicine are committed to producing independent, critical, and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the

**Confidential: Not for duplication, dissemination, or citation.**

AAN and AANEM keep separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. AAN and AANEM limit the participation of authors with substantial conflicts of interest. The AAN and AANEM forbid commercial participation in, or funding of, guideline projects. Drafts of the guideline have been reviewed by at least three AAN committees, at least one AANEM committee, a network of neurologists, *Neurology* peer reviewers, and representatives from related fields. The AAN Guideline Author Conflict of Interest Policy can be viewed at [www.aan.com](http://www.aan.com). For complete information on this process, access the 2004 AAN process manual.<sup>23</sup>

Figure 1: Recommended diagnostic flowchart for FSHD



def. = deficiency; FSHD = facioscapulohumeral muscular dystrophy; FSHD1 = FSHD type 1; FSHD2 = FSHD type 2; LGMD2A = limb-girdle muscular dystrophy type 2A.

## **REFERENCES**

1. Padberg GW. Facioscapulohumeral disease. Leiden: University of Leiden; 1982.
2. Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. *Neuromuscul Disord* 2001;11:525–529.
3. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2006;34:1–15.
4. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. *Neurology* 1997;48:38–46.
5. Stübgen JP, Stipp A. Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment. *J Neurol* 2010;257:1457–1464.
6. Wijmenga C, Brouwer OF, Padberg GW, Frants RR. Transmission of de-novo mutation associated with facioscapulohumeral muscular dystrophy. *Lancet* 1992;340:985–986.
7. van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. *Hum Mol Genet* 1993;2:2037–2042.
8. Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. *Nat Genet* 2002;32:235–236.
9. Gabriels J, Beckers MC, Ding H, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. *Gene* 1999;236:25–32.

10. Lyle R, Wright TJ, Clark LN, Hewitt JE. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. *Genomics* 1995;28:389–397.
11. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* 2010;329:1650–1653.
12. Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. *PLoS Genet* 2010;6:e1001181.
13. de Greef JC, Lemmers RJ, van Engelen BG, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. *Hum Mutat* 2009;30:1449–1459.
14. de Greef JC, Lemmers RJ, Camaño P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. *Neurology* 2010;75:1548–1554.
15. Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. *Nat Genet* 2012;44:1370–1374.
16. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* 2010;329:1650–1653.
17. Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. *Skelet Muscle* 2014;4:12.
18. Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 2010;20:471–475.



19. Attarian S, Salort-Campana E, Nguyen K, Behin A, Andoni Urtizbera J. Recommendations for the management of facioscapulohumeral muscular dystrophy in 2011. *Rev Neurol (Paris)* 2012;168:910–918.
20. Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. *Neurology* 2014;83:1453–1463.
21. Kang PB, Morrison L, Iannaccone ST, et al. Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. *Neurology*. In press.
22. Padberg GW, Lunt PW, Koch M, Fardeau M. Diagnostic criteria for facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 1991;1:231–234.
23. American Academy of Neurology. *Clinical Practice Guidelines Process Manual*, 2004 ed. St. Paul, MN: The American Academy of Neurology; 2004.  
<https://www.aan.com/Guidelines/Home/Development>. Published 2004. Accessed February 12, 2012.
24. American Academy of Neurology. *Clinical Practice Guidelines Process Manual*, 2011 ed. St. Paul, MN: The American Academy of Neurology; 2011.  
<https://www.aan.com/Guidelines/Home/Development>. Published August 2011. Accessed February 12, 2012

25. Hsu YD, Kao MC, Shyu WC, et al. Application of chromosome 4q35-qter marker (pFR-1) for DNA rearrangement of facioscapulohumeral muscular dystrophy patients in Taiwan. *J Neurol Sci* 1997;149:73–79.
26. Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. *Neurology* 1998;50:1791–1794.
27. Zeng Y, Zhang C, Su Q. Gene diagnosis of facioscapulohumeral muscular dystrophy [in Chinese]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2001;18:213–215.
28. Goto K, Lee JH, Matsuda C, et al. DNA rearrangements in Japanese facioscapulohumeral muscular dystrophy patients: clinical correlations. *Neuromuscul Disord* 1995;5:201–208.
29. Scionti I, Greco F, Ricci G, et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of facioscapulohumeral muscular dystrophy. *Am J Hum Genet* 2012;90:628–635.
30. Ricci E, Galluzzi G, Deidda G, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. *Ann Neurol* 1999;45:751–757.
31. Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. *Am J Hum Genet* 2007;81:884–894.
32. Spurlock G, Jim HP, Upadhyaya M. Confirmation that the specific SSLP microsatellite allele 4qA161 segregates with facioscapulohumeral muscular dystrophy (FSHD) in a cohort of multiplex and simplex FSHD families. *Muscle Nerve* 2010;42:820–821.

33. Köhler J, Röhrig D, Bathke KD, Koch MC. Evaluation of the facioscapulohumeral muscular dystrophy (FSHD1) phenotype in correlation to the concurrence of 4q35 and 10q26 fragments. *Clin Genet* 1999;55:88–94.
34. Statland JM, Tawil R. Risk of functional impairment in facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2014;49:520–527.
35. Lunt PW, Jardine PE, Koch M, et al. Phenotypic-genotypic correlation will assist genetic counseling in 4q35-facioscapulohumeral muscular dystrophy. *Muscle Nerve Suppl* 1995;(2):S103–S109.
36. Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. *Ann Neurol* 1996;39:744–748.
37. Sakellariou P, Kekou K, Fryssira H, et al. Mutation spectrum and phenotypic manifestation in FSHD Greek patients. *Neuromuscul Disord* 2012;22:339–349.
38. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. *Neurology* 2004;63:176–178.
39. Kilmer DD, Abresch RT, McCrory MA, et al. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. *Am J Phys Med Rehabil* 1995;74(5 Suppl):S131–S139.
40. de Visser M, de Voogt WG, la Rivière GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. *Muscle Nerve* 1992;15:591–596.

## E-REFERENCES

- e1. Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. *J Am Coll Cardiol* 1990;15:292–299.
- e2. Galetta F, Franzoni F, Sposito R, et al. Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 2005;15:403–408.
- e3. Trevisan CP, Pastorello E, Armani M, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. *Eur Neurol* 2006;56:1–5.
- e4. Laforêt P, de Toma C, Eymard B, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. *Neurology* 1998;51:1454–1456.
- e5. Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. *Neurology* 2013;80:1247–1250.
- e6. Nakagawa M, Matsuzaki T, Higuchi I, et al. Facioscapulohumeral muscular dystrophy: clinical diversity and genetic abnormalities in Japanese patients. *Intern Med* 1997;36:333–339.
- e7. Padberg GW, Brouwer OF, de Keizer RJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. *Muscle Nerve Suppl* 1995;2:S73–S80.
- e8. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. *Brain* 1987;110:631–648.
- e9. Trevisan CP, Pastorello E, Ermani M, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. *Audiol Neurootol* 2008;13:1–6.
- e10. Rogers MT, Zhao F, Harper PS, Stephens D. Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 2002;12:358–365.
- e11. Lutz KL, Holte L, Kliethermes SA, Stephan C, Mathews KD. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. *Neurology* 2013;81:1374–1377.
- e12. Padua L, Aprile I, Frusciante R, et al. Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2009;40:200–205.
- e13. Jensen MP, Hoffman AJ, Stoelb BL, Abresch RT, Carter GT, McDonald CM. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. *Arch Phys Med Rehabil* 2008;89:320–328.
- e14. Guy-Coichard C, Nguyen DT, Delorme T, Boureau F. Pain in hereditary neuromuscular disorders and myasthenia gravis: a national survey of frequency, characteristics, and impact. *J Pain Symptom Manage* 2008;35:40–50.
- e15. van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. *Neurology* 2004;63:702–708.
- e16. Kissel JT, McDermott MP, Mendell JR, et al; FSH-DY Group. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. *Neurology* 2001;57:1434–1440.
- e17. van der Kooi EL, Kalkman JS, Lindeman E, et al. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. *J Neurol* 2007;254:931–940.

- e18. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. *Ann Neurol* 2008;63:561–571.
- e19. Tawil R, McDermott MP, Pandya S, et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. *Neurology* 1997;48:46–49.
- e20. Elsheikh BH, Bollman E, Peruggia M, King W, Galloway G, Kissel JT. Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy. *Neurology* 2007;68:1428–1429.
- e21. Copeland SA, Levy O, Warner GC, Dodenhoff RM. The shoulder in patients with muscular dystrophy. *Clin Orthop Relat Res* 1999;(368):80–91.
- e22. Rhee YG, Ha JH. Long-term results of scapulothoracic arthrodesis of facioscapulohumeral muscular dystrophy. *J Shoulder Elbow Surg* 2006;15:445–450.
- e23. Diab M, Darras BT, Shapiro F. Scapulothoracic fusion for facioscapulohumeral muscular dystrophy. *J Bone Joint Surg Am* 2005;87:2267–2275.
- e24. Krishnan SG, Hawkins RJ, Michelotti JD, Litchfield R, Willis RB, Kim YK. Scapulothoracic arthrodesis: indications, technique, and results. *Clin Orthop Relat Res* 2005;(435):126–133.
- e25. Jakab E, Gledhill RB. Simplified technique for scapulocostal fusion in facioscapulohumeral dystrophy. *J Pediatr Orthop* 1993;13:749–751.
- e26. Andrews CT, Taylor TC, Patterson VH. Scapulothoracic arthrodesis for patients with facioscapulohumeral muscular dystrophy. *Neuromuscul Disord* 1998;8:580–584.
- e27. Giannini S, Faldini C, Pagkrati S, et al. Fixation of winged scapula in facioscapulohumeral muscular dystrophy. *Clin Med Res* 2007;5:155–162.
- e28. Giannini S, Ceccarelli F, Faldini C, Pagkrati S, Merlini L. Scapulopexy of winged scapula secondary to facioscapulohumeral muscular dystrophy. *Clin Orthop Relat Res* 2006;449:288–294.
- e29. Demirhan M, Uysal O, Atalar AC, Kilicoglu O, Serdaroglu P. Scapulothoracic arthrodesis in facioscapulohumeral dystrophy with multifilament cable. *Clin Orthop Relat Res* 2009;467:2090–2097.
- e30. Bunch WH, Siegel IM. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy. Review of seventeen procedures with three to twenty-one-year follow-up. *J Bone Joint Surg Am* 1993;75:372–376.
- e31. Berne D, Laude F, Laporte C, Fardeau M, Sailant G. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy. *Clin Orthop Relat Res* 2003;409:106–113.
- e32. Olsen DB, Ørngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. *Neurology* 2005;64:1064–1066.
- e33. Ambrosino N, Carpenè N, Gherardi M. Chronic respiratory care for neuromuscular diseases in adults. *Eur Respir J* 2009;34:444–451.
- e34. Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts AC. Strength training and aerobic exercise training for muscle disease. *Cochrane Database Syst Rev* 2013;7:CD003907.
- e35. US Department of Health and Human Services Office of Disease Prevention and Health Promotion. Additional Considerations for Some Adults. In: *Physical Activity Guidelines for Americans*; chap 7. <http://www.health.gov/paguidelines/guidelines/chapter7.aspx>. Published September 2008. Accessed October 1, 2012.

NEUROLOGY MS ID#: NEUROLOGY/2014/626812

MS TITLE: Evidence-based Guideline: Evaluation, Diagnosis, and Management of Facioscapulohumeral Muscular Dystrophy

26 November 2014

Dear Mr. Development Editor:

Your paper was reviewed and needs revisions.

Please visit <http://submit.neurology.org> and log in to your Author Area. See your "Manuscripts with decisions" queue for access to the comments of the reviewer(s).

Some helpful style points to consider:

- Be clear and direct; avoid the passive voice.
- Do not reiterate material from previous sections of the article.
- Introduction: Avoid stating the obvious; our audience consists of neurologists who already have a basic understanding of the topic. It should contain a concise statement of the problem and your hypothesis.
- Results: avoid repeating numeric data such as statistical test results that are found in the Tables.
- The Discussion should not reiterate the background or details of results. The focus should be on the impact of the findings on the field, how the results relate to the literature and the strengths and limitations of the design and data.

REVISING and 'RESPONSE TO REVIEW' REQUIREMENTS:

The reviewers' and/or editors' comments must be addressed before your revision is reconsidered. Be sure to include in the 'Response to Review' field a point-by-point list of all changes made in response to the suggestions of the reviewer(s) or the editors.

DISCLOSURES:

Disclosures of all authors that are relevant to the manuscript should appear on page 2 of the manuscript. Every author should be included in the Disclosure Statement. If an author has no relevant disclosures, please use "Dr. AUTHOR reports no disclosures."

(Please note that COMPLETE disclosures must be included on the disclosure form and will appear online exactly as entered.). After completing the required forms, please check your online disclosures by logging into the manuscript system at <http://submit.neurology.org>. Once you are logged in, click on your name in the upper left hand corner. Please note: If your paper is published, the online disclosures will appear exactly as they do in your read-only disclosure display. Please review for accuracy and readability and update your Disclosure Form as necessary.

NOTE:

You must explicitly state in the 'Response to Review' the page and paragraph number where each specific change was made. DO NOT simply reply to the reviewers and editors; in general, a response merits a change in the manuscript. If no change was made, you must explicitly state "We did not make

the change requested because...". If specific locations or explanations are not provided, the manuscript will be returned because the revision points cannot be assessed by the Editors without this information.

#### FIGURES:

If your submission includes any figures, they must be uploaded as editable (non-embedded) files in one of the following formats: Adobe PhotoShop (with layers), Adobe Illustrator, PowerPoint, Word, Excel, or Encapsulated Postscript (.eps). Note:

1) Solid, colored lines are preferred in line graphs over dotted/dashed lines. 2) Figures will be printed in Portrait view, so consider designing the figure in Portrait view (not Landscape). 3) If a figure is being reprinted from another publication, you must provide documented permission from the publisher (or other copyright holder) to reprint (or modify, if applicable) in Neurology.

Please make certain that:

1. You have accounted for all citations in added, deleted, or transposed material.
2. You have updated any "in press" references to specific citations.
3. Page 2 of your manuscript includes all disclosures for authors according to the Information for Authors.
4. All URL or web links are spelled correctly and access is valid. If a URL is included as a reference, include the access date.
5. Authors' affiliations are accurate. Corresponding author's contact information should be current. Co-authors' affiliations should reflect the institution at which the research was done.
6. The highest degree of each author is listed.
7. The citations in the revised text correspond to references at the end of the manuscript.
8. Your references have correct spelling, proper attribution, and are confirmed with original, not secondary sources. (Verify in your cover letter that you guarantee the accuracy of your references.)
9. Ensure that there are no duplicate references.
10. Tables and figures (if applicable) are cited in numerical sequence in the text.
11. Your manuscript number is included on your cover letter and the upper right corner of the title page.

Please be sure that the length of text and number of references, tables, and figures of your revised manuscript still adhere to NEUROLOGY's format requirements. Please check all specifications here: (<http://www.neurology.org/site/misc/auth2.xhtml>). If reviewer or editor requests (i.e., adding references, revision of Methods to include further text) conflict with these guidelines, please adhere to the guidelines and add an explanatory comment in your cover letter AND in the Response to the reviewers.

#### RE-SUBMITTING:

When uploading the revised version, please upload, as a supplemental file, a version of the manuscript with changes highlighted. Your revised manuscript can be uploaded in your 'Submit a Revision' queue at <http://submit.neurology.org>. Please do not create the revision until you are ready to submit the paper.

#### Open Access:

If you submitted your original manuscript after May 3, you will be prompted upon revision upload to consider Open Access (OA). For more information on this option, please review the FAQ document:

[http://www.neurology.org/site/includefiles/oa\\_faq.pdf](http://www.neurology.org/site/includefiles/oa_faq.pdf). If you choose the OA option, you will be prompted for OA payment and other OA requirements by the editorial office at a later manuscript stage (only if manuscript is accepted).

\*\*\*\*\*

NEUROLOGY is committed to a timely review process. We look forward to receiving your revision within 6 weeks (by 5 January 2015). Please let us know if you have extenuating circumstances or if you have decided not to continue the review process.

\*\*\*\*\*

We look forward to receiving your revision.

Sincerely yours,

Anthony Amato, MD, FAAN  
Associate Editor, NEUROLOGY

AAA/ms

Robert A. Gross, MD, PhD, FAAN  
Editor-in-Chief, NEUROLOGY

-----

Neurology® | 201 Chicago Ave | Minneapolis, MN 55415 tel. (612) 928-6400 | fax (612) 454-2748

NOTICE: This message may contain confidential or legally privileged information intended only for the use of the addressee(s) named above. Unauthorized use, disclosure, distribution, or copying is prohibited. If you have received this message in error, please reply to the sender and delete the original message. Thank you.



## Broad Review Comments FSH muscular dystrophy

#	Reviewer	Comments	Rating of Overall value	Action
1.	Tomas Holmlund	<ol style="list-style-type: none"> <li>1. Conciseness of conclusions: The genetics is messy and you have done a good job explaining this!</li> <li>2. Additional comments: I think this paper will help all us physicians in the clinical trenches (MDA-clinics) care for this patient group a bit better.</li> </ol>	4	None required
2.	Anonymous	<ol style="list-style-type: none"> <li>1. Clarity: The chart at the end-- needs further clarification in the test.</li> <li>2. Clinical questions:               <ol style="list-style-type: none"> <li>1. Pain- is it joint, muscle or nerve pain? What is the VAS score for the pain? Any rec. for treatment of the pain?</li> <li>2. Exercise - Although aerobic exercise is rec., the benefits of PT and OT to maintain full ROM and preventing of further mechanical disruption to ADLs and walking were not discussed.</li> <li>3. Genetics- When someone tests positive, who else in the family should be tested? at what age-- what will they be told?</li> <li>4. Is there a myositis associated with FSH?</li> <li>5. Is scapulothoracic syndrome FSH with facial sparing or a separate disease?</li> </ol> </li> <li>3. Comprehensiveness of literature review: Issues outside on Neurology to include FSH and physical therapy. What is the lifespan of someone with FSH? What systems need to be monitored in patients with FSH? Any guidelines?</li> <li>4. Additional comments: The review suggests that genetic studies are useful. What is the differential diagnosis and who should be screened?</li> </ol>	5	<ol style="list-style-type: none"> <li>1. Specific issues not identified by reviewer. Other reviewers found the chart helpful</li> <li>2.1 Regional pain described but character not further defined in the literature. There is no mention of the VAS score in the manuscript. No treatment recommendations are given because there is no literature addressing this specific issue in a systematic way.</li> <li>2.2 There is no literature addressing these issues specifically for FSHD</li> <li>2.3 This is outside the scope of this evidence-based review. The answer to such a question is dealt with by genetics counselors and is the approach is the same for all dominantly inherited diseases.</li> <li>2.5 Outside the scope of this review.</li> <li>3. There is no evidence-based literature on PT in FSHD on which to base recommendations.</li> </ol> <p>Guidelines for pain, respiratory, heart and retinal issues addressed in the guidelines</p> <ol style="list-style-type: none"> <li>4. Differential diagnosis discussed and table included that provides guidance as to who should be screened genetically.</li> </ol>

## Broad Review Comments FSH muscular dystrophy

3.	Jacinda Sampson	1. Additional comments: It does not make sense to include testing for A allele in the diagnostic flow chart when it is not clinically available, unless you have information that it will soon be offered.	4	Testing for the presence of A allele is performed commercially at the two major diagnostic laboratories in the U.S. : Athena diagnostics and University of Iowa. Text added to reflect this fact.
4.	Anonymous	No comments	4	No response needed
5.	Anonymous	<p>1. Clarity: 1) further clarification on the use of the D4Z4 deletion size in predicting disease progression--stated two contradictory statements</p> <p>2) further clarification on the utility of pulmonary function testing in patients with mild to moderate disease?</p> <p>3) How often should patients be monitored for retinal vascular disease?</p> <p>4) Is pain localized to the fascioscapulohumeral muscles involved or diffuse? Proposed pathophysiology of pain in FSHD?</p> <p>2. Timeliness: 1) More detailed description of timeline with regards to evolution of symptoms---length of time it takes for progression of descending weakness</p> <p>2) How to young children and babies present?</p>	4	<p>1.1. Not sure by which statements are deemed contradictory. The recommendation was carefully phrased to reflect the fact that the correlation between disease severity and deletion size is not robust except when the deletion is large (page 14, pp 1)</p> <p>1.2. Recommendations clarified.</p> <p>1.3 Relevant comment; there is no evidence on which to base recommendations. Nevertheless, text suggesting a reasonable approach was added for guidance.</p> <p>1.4. The literature dealing with pain defines regions of pain but not types of pain. There is no literature dealing with the pathophysiology of pain in FSHD.</p> <p>21.A wide spectrum of disease severity and rates of progression are described; therefore there is no typical timeline.</p> <p>2.2Added sentence in the introduction regarding this issue.</p>
6.	Anonymous	<p>1. Additional comments: Photographs (if appropriate for this document) of a typical patient would be useful.</p> <p>I think the recommendations are prudent, given the variable literature. I think the suggestions regarding the pattern and frequency of referral to specialists for evaluation of systemic features of FSHD is particularly useful.</p>	5	This is not in the scope of this manuscript
7.	João Cerqueira	No comments	5	No response needed
8.	Manish Parakh	<p>1. Clarity: Needs improvement in the explanation of molecular genetics.</p> <p>2. Clinical questions: Specific clinical questions have been very</p>	5	Genetics of FSHD is indeed complex. Added figure as a visual aid. 2,3,4,5 No need for response

## Broad Review Comments FSH muscular dystrophy


		<p>clearly examined</p> <p>3. Comprehensiveness of literature review: Excellent review of the literature with most of the publications cited are from high impact factor journals</p> <p>4. Conciseness of conclusions: Conclusions are concrete and of clinical significance</p> <p>5. Additional comments: The guideline document is very well written as commented above except for the fact that the molecular genetics needs to be simplified.</p>		
9.	Anonymous	<p>1. Clarity: There are typo, punctuation and english style can be improved. The different sections of the guidelines ar not well articulated. Contents are missing in methods or results that should be present for results and conclusions to make sense. (see below)</p> <p>2. Timeliness:</p> <p>3. Clinical questions:</p> <p>4. Comprehensiveness of literature review: Authors should mention main reasons and corresponding number for excluding studies as per PRISMA guidelines Authors should explain reason for different exclusion criteria on sample size for each topic There is no mention to meta-analyses methods</p> <p>5. Conciseness of conclusions: there is no mention to future pharmacological studies in research.</p> <p>the mention to STROBE criteria is not supported by any APPRAISAL data IN results.</p> <p>6. Accuracy: assessment of heterogeneity and meta-analyses methods are not explained in the methods.</p> <p>L E vel fo recommendation is missing in the text</p> <p>Evidence section should ALWAYS be analysis of evidence.</p> <p>Authors should give more information on study design for</p>	3	<p>Will revise and edit as needed.</p> <p>2,3: not clear if reviewer's comments were left our here</p> <p>4. Using AAN guidelines process (send to Gary for comment)</p> <p>5. Text of recommendations added to address this point. STROBE was invoked in the recommendations precisely because few existing studies followed STROBE recommendations.</p> <p>6. Questions for Gary Gronseth: need for additional explanation of methods. Need to add level of recommendations</p>

## Broad Review Comments FSH muscular dystrophy

		<p>obSeRvational studies.</p> <p>7. Format: Quantified results are missing in abstract. Levels of evidence are missing in the results. Some reference are missing. English style deserves a significant improvement. The term systematic evidence-based review is cofounding, as systematic review is one thing and evidence based guideline/recommendation is another.</p>		<p>7. Need more input from Gary regarding these comments.</p>
10.	Wendy Johnston	<p>1. Clarity: The section regarding cardiac requires clarification. In the text the summary of the literature states, "Six Class III studies examined surface ECG in 227 patients with FSHD.(29, 37) :Abnormalities were found in 89 or 39.2% (95% CI 33.1%–45.7%) of patients with FSHD screened. The same 6 Class III studies looked at the frequency of symptomatic or inducible supraventricular arrhythmias and found 16 these in 22 patients or 9.7% (95% CI 6.5%–14.2%)". Despite this statistic the recommendation is that routine ECG is not necessary. If the level of evidence is insufficient to recommend screening then perhaps recommending regular clinical queries about cardiac symptoms (as was recommended for pain) should be made.</p> <p>2. Conciseness of conclusions: see above.</p> <p>Also, if might be helpful to clarify the respiratory issue as to whether the restrictive disease is due to muscular weakness or to deformity of the thoracic cage in the minority who have it .</p> <p>3. Format: Please consider illustrating the genetics to underline the principles. Also, if possible, enable links to both the clinical diagnostic criteria and photos of the range of clinical presentations</p> <p>4. Additional comments: I think this is a particularly helpful evidence based guideline because of the breadth of the material covered, from genetics to surgical intervention to exercise. The molecular genetic summary was particularly well done. Unlike other AAN publications that seem to be rigidly adhering to recommendations from the highest evidence alone, resulting in no workable recommendations, this one is useful.</p>	5	<p>1.References corrected. Agree with reviewer comment. Text was added to the paragraph on recommendations for cardiac abnormalities.</p> <p>2. Agree with reviewer that pectus excavatum, relatively common in FSHD may play a role in restrictive lung disease. This is however, not addressed in the literature.</p> <p>3. Agree. Will add diagram, as mentioned above.</p> <p>4. No need for response</p>

## Broad Review Comments FSH muscular dystrophy

Please rate the overall value of this guideline on a scale of 1 to 5, where 1 is "not valuable" and 5 is "very valuable".




Clarity of document




## Broad Review Comments FSH muscular dystrophy

### Timeliness of document



1 (Poor)	0	0%
2	0	0%
3	2	20%
4	2	20%
5 (Excellent)	6	60%


### Comprehensiveness of literature review



1 (Poor)	0	0%
2	0	0%
3	1	10%
4	3	30%
5 (Excellent)	6	60%


## Broad Review Comments FSH muscular dystrophy

### Clarity and conciseness of conclusions



1 (Poor)	0	0%
2	1	10%
3	0	0%
4	5	50%
5 (Excellent)	4	40%


### Importance of clinical questions addressed



1 (Poor)	0	0%
2	0	0%
3	0	0%
4	4	40%
5 (Excellent)	6	60%


## Broad Review Comments FSH muscular dystrophy

### Accuracy



1 (Poor)	0	0%
2	1	10%
3	0	0%
4	2	20%
5 (Excellent)	7	70%

### Format



1 (Poor)	0	0%
2	1	10%
3	0	0%
4	6	60%
5 (Excellent)	3	30%



## Summary of Comments and Revisions for FSHD Evidence-Based Guideline

<u>Page</u>	<u>Line</u>	<u>Reviewer</u>	<u>Original Language</u>	<u>Suggested Change</u>
	General	Anonymous		Need abstract; highlight on what practitioners should do
	General	Anonymous		Very good document; punctuation errors (duplicate periods, miss
	General	Anonymous		Well written
	General	Anonymous		No issues with this paper

ed periods, etc.) that assume will be caught by editors

NEUROLOGY MS ID#: NEUROLOGY/2014/626812

MS TITLE: Evidence-based Guideline: Evaluation, Diagnosis, and Management of Facioscapulohumeral Muscular Dystrophy Guideline Development Editor, Rabi Tawil, John T. Kissel, Chad Rydel Heatwole, Shree Pandya, Gary Gronseth, and Michael Benatar

21 January 2015

Dear Guidelines Development Editor:

We are pleased to accept your paper for publication in NEUROLOGY (contingent on Board approval).

-----  
IMPORTANT NOTE: Your paper and its findings are embargoed. News media must not publicize the paper until 4PM EST the day of online publication. This includes processes that your institutional public relations department must follow to release any article information.  
-----

The corresponding author will receive a "Welcome to Production" letter within one business day after your paper has been transmitted to our publisher, Wolters Kluwer. Approximately two weeks later, the corresponding author will be notified via email that copyediting is complete and that the composed proof will be ready for review within a few days thereafter. The proof will come via e-mail from Wolterskluwer.com.

The subject line will read "Please Pick Up Your Proofs for Your Article in Neurology."

You must be available to review your proofs within 48 hours (two business days) of receipt of the proof notification. If you anticipate being away from email after receiving your Welcome Letter, please make arrangements for the proofs to be sent to a co-author for review. We are not able to modify the production schedule to accommodate author absences.

-----  
INQUIRIES

Pre-production

Print publication date: Sandi Moriarity ([smoriarity@neurology.org](mailto:smoriarity@neurology.org))

Production

Page proofs: Alex Lazerow ([Alexandra.Lazerow@wolterskluwer.com](mailto:Alexandra.Lazerow@wolterskluwer.com)) only after receipt of the Welcome Letter

Embargo date: Alex Lazerow ([Alexandra.Lazerow@wolterskluwer.com](mailto:Alexandra.Lazerow@wolterskluwer.com)) only when returning proofs

Embargo policy and press release information: Rachel Seroka ([rseroka@aan.com](mailto:rseroka@aan.com)) only after returning proofs  
-----

Please make note that we have attached the final document of your most recently-submitted article. This is the version of record and will be sent to the publisher.

We advise you to review this version and send any changes in a tracked Word document. If substantive changes (additional references, data, patient numbers, statistics) are proposed later during the proof stage, publication may be substantially delayed.

-----  
Many thanks for your contribution to NEUROLOGY. As a valued author, we are pleased to offer you a 20% discount on any LWW book.  
Please go to <http://journals.lww.com/dm/Pages/BookDiscountMedical.aspx> for further details.  
-----

Sincerely,

Robert A. Gross, MD, PhD, FAAN  
Editor-in-Chief, NEUROLOGY  
RAG/sq

-----  
Neurology® | 201 Chicago Ave | Minneapolis, MN 55415  
tel. (612) 928-6400 | fax (612) 454-2748

NOTICE: This message may contain confidential or legally privileged information intended only for the use of the addressee(s) named above. Unauthorized use, disclosure, distribution, or copying is prohibited. If you have received this message in error, please reply to the sender and delete the original message. Thank you.